

(12) United States Patent Welford et al.

(54) SYSTEMS AND METHODS FOR

AMPLIFYING LIGHT

(71) Applicant: VOLCANO CORPORATION, San

Diego, CA (US)

Inventors: **David Welford**, Danvers, MA (US);

Badr Elmaanaoui, Billerica, MA (US)

(73)Assignee: Volcano Corporation, San Diego, CA

(US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 117 days.

(21) Appl. No.: 14/045,909

(22)Filed: Oct. 4, 2013

(65)**Prior Publication Data**

> US 2014/0098412 A1 Apr. 10, 2014

Related U.S. Application Data

Provisional application No. 61/710,424, filed on Oct. 5, 2012.

(51) Int. Cl.

H01S 5/028 H01S 5/50

(2006.01)(2006.01)

(Continued)

(52) U.S. Cl.

CPC H01S 5/0287 (2013.01); H01S 5/0288 (2013.01); H01S 5/50 (2013.01); G01N 21/4795 (2013.01); H01S 5/02216 (2013.01);

H01S 2301/02 (2013.01)

Field of Classification Search

CPC A61B 5/0066; A61B 3/102; G01B 9/020911; G06T 2207/10101; H01S 5/0287; H01S 5/0288; H01S 5/50

See application file for complete search history.

(10) Patent No.:

(56)

EP

(45) Date of Patent:

References Cited U.S. PATENT DOCUMENTS

1/1967 Werner 3,301,258 A

3,484,713 A * 12/1969 Fenner H01L 33/00 148/DIG. 107

US 9,478,940 B2

Oct. 25, 2016

(Continued)

FOREIGN PATENT DOCUMENTS

EP1041373 A2 10/2000 1/2002 01172637 A1

(Continued)

OTHER PUBLICATIONS

Little et al., 1991, The underlying coronary lesion in myocardial infarction:implications for coronary angiography, Clinica Cardiology, 14(11):868-874.


(Continued)

Primary Examiner — Eric Bolda (74) Attorney, Agent, or Firm — Brown Rudnick LLP; Thomas C. Meyers

(57)**ABSTRACT**

The invention relates to optical system including light sources that amplify light using a gain medium. Systems and method of the invention are provided for amplifying light while inhibiting reflections at a peak gain of the gain medium, thereby suppressing parasitic lasing. This allows a system to use a broad range of wavelengths without parasitic lasing, thereby increasing the useable range of a tunable optical filter. In this manner, light at wavelengths not at a peak gain can be used effectively, and the gain medium of an optical amplifier does not limit use of a system to a narrow range of wavelengths associated with a peak gain of the gain medium. A single optical system according to the invention can thus be used for applications that require a broad range of wavelengths.

18 Claims, 15 Drawing Sheets



US 9,478,940 B2

Page 2

(51)	Int. Cl.		(000 (01)	5,183,048 5,188,632		2/1993	Eberle Goldenberg
	G01N 21/47		(2006.01)	5,191,586		3/1993	
	H01S 5/022		(2006.01)	5,201,316	A		Pomeranz et al.
(50)	n		C!4-1	5,202,745 5,203,779	A		Sorin et al. Muller et al.
(56)	Re	eieren	ces Cited	5,220,922			Barany
	U.S. PA	TENT	DOCUMENTS	5,224,953	A		Morgentaler
				5,226,421 5,240,003			Frisbie et al. Lancee et al.
			Cormack et al.	5,240,437			Christian
	, ,)/1974)/1974	Antoshkiw Tate	5,242,460	Α		Klein et al.
			Yamashita et al.	5,243,988 5,257,974		9/1993 11/1993	Sieben et al.
			Mizuno et al.	5,266,302		11/1993	Peyman et al.
			Schultz Dorsey	5,267,954	A	12/1993	Nita
	4,432,370 A 2	2/1984	Hughes et al.	5,268,910 5,295,209			Huber
			Gould et al.	5,301,001			Murphy et al.
			Wilson Segal et al.	5,312,425	Α	5/1994	Evans et al.
	4,682,895 A 7	/1987	Costello	5,313,949		5/1994 5/1994	
			Palmaz	5,313,957 5,319,492			Dorn et al.
	, ,		Cameron Bonzel	5,321,501	Α		Swanson et al.
	4,766,386 A 8	3/1988	Oliver et al.	5,325,198 5,336,178			Hartley et al. Kaplan et al.
			Simpson et al.	5,346,689			Peyman et al.
		/1989 /1989	Nestor	5,348,017	Α	9/1994	Thornton et al.
	4,803,639 A 2	2/1989	Steele et al.	5,348,481 5,353,798		9/1994 10/1994	
			Cabilly et al.	5,358,409		10/1994	
			Warrington Martinelli et al.	5,358,478	Α	10/1994	Thompson et al.
	4,824,435 A 4	/1989	Giesy et al.	5,368,037 5,373,845			Eberle et al. Gardineer et al.
			de Toledo et al.	5,373,849			Maroney et al.
	, ,		Littleford et al. Griffith et al.	5,375,602	Α	12/1994	Lancee et al.
	4,864,578 A 9		Proffitt et al.	5,377,682 5,383,853			Ueno et al. Jung et al.
			Adams	5,387,193		2/1995	
			Kanamori Yock et al.	5,396,328	Α	3/1995	Jestel et al.
		/1990		5,397,355 5,405,377		3/1995 4/1995	Marin et al.
			Proudian et al.	5,411,016		5/1995	Kume et al.
			Goodin et al. Shockey et al.	5,419,777	A	5/1995	Hofling
			de Toledo	5,421,338			Crowley et al. Dale et al.
		3/1990		5,423,806 5,427,118			Nita et al.
			Crowley et al. Falk et al.	5,431,673	Α	7/1995	Summers et al.
	4,987,412 A 1	/1991	Vaitekunas et al.	5,436,459 5,436,759			Koch et al. Dijaili et al.
			Murphy-Chutorian	5,439,139			Brovelli
		3/1991 3/1991	Chin et al. Yock	5,443,457			Ginn et al.
	5,024,234 A 6	5/1991	Leary et al.	5,453,575 5,456,693			O'Donnell et al. Conston et al.
			Anderson et al. Katz et al.	5,459,570			Swanson et al.
	, ,	3/1991		5,480,388			Zadini et al.
	5,039,193 A 8		Snow et al.	5,485,845 5,492,125			Verdonk et al. Kim et al.
		3/1991 2/1991	Yock Fox et al.	5,496,997	Α	3/1996	Pope
			Scribner et al.	5,507,761		4/1996	
			Knute	5,512,044 5,514,128		4/1996 5/1996	Duer Hillsman et al.
			de Toledo Ingebrigtsen et al.	5,529,674	A		Hedgcoth
			Pomeranz	5,541,730			Chaney
			Jang et al.	5,546,717 5,546,948			Penczak et al. Hamm et al.
		5/1992 5/1992	Hess Corl et al.	5,565,332		10/1996	Hoogenboom et al.
			Huber	5,568,311	A *	10/1996	Matsumoto B82Y 20/00
	5,135,486 A 8		Eberle et al.	5,573,520	Α	11/1996	359/344 Schwartz et al.
			Sahatjian et al. Huber 372/6	5,581,638			Givens et al.
			Holmbo et al.	5,586,054	A	12/1996	Jensen et al.
			Lau et al.	5,592,939 5,596,079			Martinelli Smith et al.
			Christian et al. Eberle et al.	5,596,079 5,598,844			Diaz et al.
			Christian et al.	5,609,606			O'Boyle
			Bom et al.	5,630,806			Inagakı et al.
			Hofmann Christian	5,651,366			Liang et al. Malinowski et al.
	5,178,159 A 1	./ 1993	Christian	5,660,180	A	8/199/	mannowski et al.

(56) Referen	nces Cited	6,179,809 B1 6,186,949 B1		Khairkhahan et al. Hatfield et al.
U.S. PATENT	DOCUMENTS	6,190,353 B1	2/2001	Makower et al.
5 665 400 4 0/1005	W/ 1.1 1	6,195,200 B1* 6,200,266 B1		DeMarco et al 359/337.21 Shokrollahi et al.
	Welch et al. Keown	6,200,268 B1	3/2001	Vince et al.
5,672,877 A 9/1997	Liebig et al.	6,203,537 B1		Adrian
	Halliburton Walker et al	6,208,415 B1 6,210,332 B1		De Boer et al. Chiao et al.
	Walker et al. Dubrul et al.	6,210,339 B1	4/2001	Kiepen et al.
5,745,634 A 4/1998	Garrett et al.	6,212,308 B1		Donald Grabek et al.
	Slager Leavitt	6,231,518 B1 6,245,066 B1		Morgan et al.
5,780,958 A 7/1998	Strugach et al.	6,249,076 B1	6/2001	Madden et al.
	Corsini et al 372/6	6,249,373 B1* 6,254,543 B1		Woodward 359/344 Grunwald et al.
	Froggatt Lary et al.	6,256,090 B1		Chen et al.
5,803,083 A 9/1998	Buck et al.	6,258,052 B1	7/2001	
	Osborne et al. Alekseev et al.	6,261,246 B1 6,275,628 B1		Pantages et al. Jones et al.
	Fontirroche et al.	6,283,921 B1	9/2001	Nix et al.
5,824,520 A 10/1998	Mulligan-Kehoe	6,283,951 B1 6,295,308 B1	9/2001 9/2001	Flaherty et al.
5,827,313 A 10/1998 5,830,222 A 11/1998	Ream Makower			Snow et al.
, ,	Gupta et al.		11/2001	
	Davila et al.			Vahala et al 359/326 Stewart et al.
, ,	Eberle et al. Wischmann et al.	6,328,696 B1	12/2001	Fraser
5,873,835 A 2/1999	Hastings et al.	6,343,168 B1		Murphy et al. Burns et al.
	Kydd Togino	6,343,178 B1 6,350,240 B1		Song et al.
5,914,978 A * 6/1999	Welch H01S 5/026	6,364,841 B1	4/2002	White et al.
	372/102	6,366,722 B1 6,367,984 B1		Murphy et al. Stephenson et al.
	Jacobsen et al. O'Donnell et al.	6,373,970 B1		Dong et al.
	Adrian et al.	6,375,615 B1		Flaherty et al.
	Hamm	6,375,618 B1 6,375,628 B1		Chiao et al. Zadno-Azizi et al.
	Berg et al. LeGrange et al 385/27	6,376,830 B1		Froggatt et al.
5,974,521 A 10/1999	Akerib	6,379,352 B1		Reynolds et al.
	Chow et al. Das et al.	6,381,350 B1 6,387,124 B1		Klingensmith et al. Buscemi et al.
	Massicott et al 359/337	6,396,976 B1	5/2002	Little et al.
5,997,523 A 12/1999		6,398,792 B1 6,400,495 B1*		O'Connor Zayhowski 359/333
5,999,548 A * 12/1999	Mori	6,417,948 B1		Chowdhury et al.
	Murphy et al.	6,419,644 B1		White et al.
	Willard et al. Mandeville et al.	6,421,164 B2 6,423,012 B1		Tearney et al. Kato et al.
6,031,071 A 2/2000 6,036,889 A 3/2000		6,426,796 B1	7/2002	Pulliam et al.
6,043,883 A 3/2000	Leckel et al.	6,428,041 B1 6,428,498 B2		Wohllebe et al. Uflacker
	White et al. Stoltze et al.	6,429,421 B1	8/2002	Meller et al.
6,068,638 A 5/2000	Makower	6,440,077 B1		Jung et al.
6,074,362 A 6/2000	Jang et al. Belef et al.	6,443,903 B1 6,450,964 B1		White et al. Webler
	Baker et al.	6,457,365 B1	10/2002	Stephens et al.
6,091,496 A 7/2000	Hill		10/2002	Pan Weldon et al.
	Sorin et al. Foltz et al.			Sumanaweera
6,095,976 A 8/2000	Nachtomy et al.		11/2002	
	Guenther, Jr. et al.			Chiao et al. Chenal et al.
	Torp et al. Bosma et al.	6,501,551 B1		Tearney et al.
6,102,938 A 8/2000	Evans et al.	6,504,286 B1		Porat et al.
	Corl et al. Grunwald	6,508,824 B1 6,514,237 B1		Flaherty et al. Maseda
	Eberle et al.	6,520,269 B2	2/2003	Geiger et al.
	Tearney et al.	6,520,677 B2 6,535,764 B2	2/2003	lizuka Imran et al.
	Palermo Thoma et al.	6,538,778 B1		Leckel et al.
6,146,328 A 11/2000	Chiao et al.	6,544,217 B1	4/2003	Gulachenski
	Prause et al.	6,544,230 B1 6,545,760 B1		Flaherty et al. Froggatt et al.
	Dower et al. Masters	6,545,760 B1 6,546,272 B1		MacKinnon et al.
6,152,878 A 11/2000	Nachtomy et al.	6,551,250 B2	4/2003	Khalil
	Makower	6,566,648 B1		Froggatt
6,165,127 A 12/2000 6,176,842 B1 1/2001	Crowley Tachibana et al.	6,567,430 B1* 6,570,894 B2		Freeman et al 372/3 Anderson
-,		, ,		

(56)			Referen	ces Cited	6,952,603 6,954,737			Gerber et al. Kalantar et al.	
		HS E	PATENT	DOCUMENTS	6,954,737 6.958.042		10/2005		
		0.5. 1	AILIVI	DOCUMENTS	6,961,123			Wang et al.	
	6,572,555	B2	6/2003	White et al.	6,966,891		11/2005	Ookubo et al.	
	6,579,311			Makower	6,969,293		11/2005		
	6,584,335			Haar et al.	6,969,395		11/2005		
	6,592,612			Samson et al.	6,985,234 6,992,813		1/2006	Anderson Tanaka et al	350/333
	6,594,448			Herman et al. Makower et al.	7,004,963			Wang et al.	339/333
	6,602,241 6,611,322			Nakayama et al.	7,006,231			Ostrovsky et al.	
	6,611,720			Hata et al.	7,010,458		3/2006		
	6,612,992		9/2003	Hossack et al.	7,024,025			Sathyanarayana	
	6,615,062			Ryan et al.	7,027,211		4/2006	Ruffa Tucker et al.	
	6,615,072			Izatt et al.	7,027,743 7,033,347			Appling	
	6,621,562 6,631,284			Durston Nutt et al.	7,035,484		4/2006	Silberberg et al.	
	6,638,227		10/2003		7,037,269			Nix et al.	
	6,645,152	BI		Jung et al.	7,042,573			Froggatt	
	6,646,745	B2		Verma et al.	7,044,915			White et al.	
	6,655,386	B1	12/2003	Makower et al.	7,044,964 7,048,711			Jang et al. Rosenman et al.	
				Ajima et al 385/123 Vardi et al.	7,048,711 7,049,306			Konradi et al.	
	6,659,957 6,660,024			Flaherty et al.	7,058,239			Singh et al.	
	6,663,565			Kawagishi et al.	7,060,033			White et al.	
	6,665,456	B2		Dave et al.	7,060,421			Naundorf et al.	
	6,669,716	B1		Gilson et al.	7,063,679 7,068,852		6/2006	Maguire et al.	
	6,671,055			Wavering et al.	7,008,832 7.074.188			Nair et al.	
	6,673,015 6,673,064			Glover et al. Rentrop	7,095,493		8/2006		
	6,685,648			Flaherty et al.	7,110,119			Maestle	
	6,689,056	B1	2/2004	Kilcoyne et al.	7,113,875			Terashima et al.	
	6,689,144			Gerberding	7,123,777 7,130,054			Rondinelli et al. Ostrovsky et al.	
	6,696,173 6,701,044			Naundorf et al. Arbore et al.	7,130,034 7,139,440			Rondinelli et al.	
	6,701,044			Halperin et al.	7,153,299	В1		Tu et al.	
	6,709,444			Makower	7,171,078	B2		Sasaki et al.	
	6,712,836	B1	3/2004	Berg et al.	7,175,597			Vince et al.	
	6,714,703			Lee et al.	7,177,491 7,190,464			Dave et al. Alphonse	
	6,719,717			Johnson et al.	7,190,404 7,215,802		5/2007	Klingensmith et al.	
	6,725,073 6,726,677			Motamedi et al. Flaherty et al.	7,218,811		5/2007	Shigenaga et al.	
	6,730,107			Kelley et al.	7,224,519	B2 *	5/2007	Shin I	
	6,733,474			Kusleika	7 226 012	D 1	6/2007	D-11	359/344
	6,738,144			Dogariu	7,236,812 7,245,125			Ballerstadt et al. Harer et al.	
	6,740,113 6,746,464		5/2004 6/2004	Makower	7,245,789			Bates et al.	
	6,780,157			Stephens et al.	7,249,357	B2		Landman et al.	
	6,795,188			Ruck et al.	7,257,137	B2		Robbins et al.	
	6,795,196			Funakawa	7,291,146 7,292,715		11/2007	Steinke et al.	
	6,798,522			Stolte et al.	7,292,713 7.292,885			Scott et al.	
	6,822,798 6,830,559		12/2004	Wu et al.	7,294,124			Eidenschink	
	6,832,024			Gerstenberger et al.	7,300,460			Levine et al.	
	6,842,639	B1	1/2005	Winston et al.	7,335,161			Von Arx et al.	
	6,847,449			Bashkansky et al.	7,337,079 7,355,716			Park et al. de Boer et al.	
	6,855,115			Fonseca et al.	7,356,367			Liang et al.	
	6,856,138 6,856,400			Bohley Froggatt	7,358,921			Snyder et al.	
	6,856,472			Herman et al.	7,359,062			Chen et al.	
	6,860,867	B2		Seward et al.	7,359,554			Klingensmith et al.	
	6,866,670			Rabiner et al.	7,363,927 7,366,376			Ravikumar Shishkov et al.	
	6,878,113 6,886,411			Miwa et al.	7,382,949			Bouma et al.	
	6,891,984			Kjellman et al. Petersen et al.	7,387,636			Cohn et al.	
	6,895,106			Wang et al.	7,391,520			Zhou et al.	
	6,898,337			Averett et al.	7,397,935			Kimmel et al.	
	6,900,897			Froggatt	7,399,095 7,408,648			Rondinelli Kleen et al.	
	6,912,051 6,916,329		6/2005 7/2005		7,408,048 7,414,779			Huber et al.	
	6,922,498		7/2005		7,440,087			Froggatt et al.	
	6,937,346	B2	8/2005	Nebendahl et al.	7,447,388		11/2008	Bates et al.	
	6,937,696			Mostafavi	7,449,821		11/2008		
	6,943,939			DiJaili et al.	7,450,165 RE40,608		11/2008		
	6,947,147 6,947,466			Motamedi et al. Anikitchev H01S 5/026	7,458,967			Glover et al. Appling et al.	
	U,J-17, 1 100	102	J1 2003	372/50.1	7,438,967 7,463,362			Lasker et al.	
	6,947,787		9/2005	Webler	7,463,759	B2	12/2008	Klingensmith et al.	
	6,949,094	B2	9/2005	Yaron	7,491,226	B2	2/2009	Palmaz et al.	

U.S. PATENT DOCUMENTS 8,049,478 B. 1 1/2011 Livet at al. 7,513,706 B2 4/2009 Prognet et al. 8,052,003 B2 11/2011 Molter et al. 7,573,704 B2 5/000 WanDyke 8,052,003 B2 11/2011 Molter et al. 7,533,707 B2 5/000 WanDyke 8,052,003 B2 11/2011 Molter et al. 7,533,707 B2 5/000 Prognet et al. 8,052,003 B2 11/2011 Molter et al. 7,533,707 B2 5/000 Prognet et al. 8,052,003 B2 11/2011 Molter et al. 7,533,707 B2 5/000 Prognet et al. 8,052,003 B2 B2 11/2011 Molter et al. 7,533,707 B2 7/000 Molters et al. 8,052,003 B2 B2 11/2011 Molter et al. 8,052,003 B2 B2 11/2012 Molter et al. 8,052,003 B2 B2 11/2012 Molter et al. 8,062,003 B2 11/2019 Molter et al. 8,116,003 B2 11/2019 Molter	(56) Referen	nces Cited	8,047,996 B2		Goodnow et al.
7,515,276 12 4-2009 Proggast et al. 8,05,205 12 11/2011 Muller et al. 7,537,594 12 11/2011 Muller et al. 8,05,205 12 11/2011 Muller et al. 1,537,594 12 11/2012 Muller et al. 1,537,594 13 11/2019	IIS DATENT	DOCUMENTS			
1.537.794 12 2.0009 Varid et al. 8.057.394 12 11/2011 Dala-Krishaa 7.534.216 12 2.0009 Peng et al. 8.059.203 11/2011 Bales et al. 1.535.797 12 2.0009 Peng et al. 8.079.800 13 12/2011 Lock et al. 1.535.797 12 2.0009 Peng et al. 8.079.800 13 12/2012 Lock et al. 1.535.797 12 2.0009 Peng et al. 8.079.800 13 12/2012 Lock et al. 1.535.797 13 2.0009 Peng et al. 8.079.800 13 12/2012 Varight et al. 1.535.797 13 12.0009 Peng et al. 8.108.808 12 12/2012 Varight et al. 1.535.797 13 12.0009 Peng et al. 8.108.808 12 12/2012 Varight et al. 1.535.797 Peng et al. 1.535.797	U.S. TATENT	DOCUMENTS			
7.537.594 B2 5.2009 Varied et al. 8057.394 B2 11.2011 Dala-Krishna (1.53) September 1.2012 Market et al. 8059.2013 B1 11.2011 Bala-Krishna (1.53) September 1.2012 Market et al. 8059.2014 B1.2012 Market et al. 8059.2014 B1.	7,515,276 B2 4/2009	Froggatt et al.			
1.535,797 12 5.2009 Pong et al. 8,070,800 82 12,001 Lock et al.	7,527,594 B2 5/2009	Vardi et al.			
7-54-7-304 12	7,534,251 B2 5/2009	WasDyke			
7.564,946 B2 7.2009 Sattler et al. 8,088,102 B2 12012 Adams et al. 7.573,747 B2 82090 Camus et al. 8,103,038 B2 12012 Wright et al. 7.573,747 B2 92009 Xi et al. 8,108,038 B2 12012 Castella et al. 1.573,857 B2 92009 Xi et al. 8,108,038 B2 12012 Castella et al. 1.574,764,729 B2 122009 Choma et al. 8,114,026 B2 22012 Castella et al. 1.574,764,729 B2 122010 Park et al. 8,114,026 B2 22012 Castella et al. 1.574,764,729 B2 122010 Park et al. 8,114,028 B2 22012 Castella et al. 1.574,764,729 B2 122010 Park et al. 8,114,038 B2 22012 Willier et al. 1.574,764,729 B2 22010 Park et al. 8,125,339 B2 22012 Sinc et al. 1.574,764,729 B2 22010 Park et al. 8,125,339 B2 22012 Sinc et al. 1.574,764,764,764,764,764,764,764,764,764,7	7,535,797 B2 5/2009 7,547,304 B2 6/2009				
7.573,471 B2 82090 Camus et al. 8,100,338 B2 12012 Wright et al. 7,753,187 B2 92090 Xu et al. 8,104,379 B2 12012 Gym et al. 7,763,187 B2 92090 Xu et al. 8,104,379 B2 12012 Gym et al. 8,104,379 B2 22012 Galdonik et al. 8,116,003 B2 22012 Galdonik et al. 7,765,715 B2 22010 Park et al. 8,116,003 B2 22012 Galdonik et al. 7,765,715 B2 22010 Park et al. 8,135,399 B2 22012 Sym et al. 8,104,379 B2 32012 Weber et al. 8,104,379 B2 32010 Sym et al. 8,104,379 B2 32012 Jaffs et al. 8,104,379 B2 32010 Jaffs et					
Topol.165 B2 102000 Townsond et al. S.108.030 B2 12012 Castella et al.	7,577,471 B2 8/2009				
Total Tota					
7-633,627 B2 122090 Choma et al. 8,116,600 B2 22012 Petersen et al. 7-664,529 B2 12010 Park et al. 8,125,290 B2 22010 Shine et al. 8,135,200 B2 23010 Shine et al. 8,135,200 B2 24010 Shine et al. 8,233,300 B2 24010 Shine et					
7,668,715 B2 2,2010 Park et al. 7,660,492 B2 2,2010 Bates et al. 8,133,269 B2 3,2010 Evelower et al. 8,133,269 B2 3,2010 Evelower et al. 8,148,377 B2 3,2010 McGraw et al. 8,148,377 B2 4,2012 Jaine et al. 7,660,204 B2 2,2010 McGraw et al. 8,148,377 B2 4,2012 Jaine et al. 7,660,304 B2 3,2010 McGraw et al. 8,148,377 B2 4,2012 Jaine et al. 7,768,391 B2 3,2010 Stohr et al. 8,177,390 B2 3,2010 Edition et al. 8,177,390 B2 5,2010 Bummer et al. 8,177,390 B2 6,2010 Bummer et al. 8,187,277 B2 5,2012 Jaine et al. 7,734,307 B2 6,2010 Lasker et al. 8,187,277 B2 5,2012 Jaine et al. 7,743,189 B2 6,2010 Stohr et al. 8,187,267 B2 5,2012 Jaine et al. 7,743,189 B2 6,2010 Bummer et al. 8,187,367 B2 5,2012 Hu et al. 7,769,361 B2 7,2010 Nix et al. 8,187,367 B2 5,2012 Hu et al. 7,769,361 B2 7,2010 Nix et al. 8,187,367 B2 5,2012 Hu et al. 7,776,995 B2 7,2010 Nix et al. 8,205,438 B2 6,2010 Gregorich et al. 8,205,438 B2 6,2010 Gregorich et al. 8,205,438 B2 6,2010 Gregorich et al. 8,205,438 B2 7,2012 Corresponde et al. 7,776,995 B2 7,2010 Nix et al. 8,205,438 B2 7,2012 Corresponde et al. 8,2					
7,660,452 82 2,2010 Zwirn et al. 5,133,199 B2 3,2012 Weber et al. 7,666,204 B2 2,2010 Thomton et al. 8,149,708 B2 3,2010 Zwirn et al. 8,149,708 B2 4,2012 Jiang et al. 4,2012 J					
7.660,492 B2 22010 Bates et al. 8,133,269 B2 32012 Flecksenhar et al. 7.676,2790 B2 32010 McGraw et al. 8,148,877 B2 42012 Jiang et al. 7.672,790 B2 32010 McGraw et al. 8,148,877 B2 42012 Jiang et al. 359,344 7,680,247 B2 32010 McGraw et al. 8,148,877 B2 42012 Jiang et al. 359,344 7,741,413 B2 52010 Fledoma et al. 8,177,809 B2 42012 Jiang et al. 359,344 7,741,413 B2 52010 Fledoma et al. 8,187,180 B2 52012 Jaffe et al. 1,743,347 B2 6,2010 Fledoma et al. 8,187,180 B2 52012 Jaffe et al. 1,743,347 B2 6,2010 Binmer et al. 8,187,180 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Stephens et al. 8,187,267 B2 52012 Hancock et al. 1,743,187 B2 6,2010 Stephens et al. 8,187,267 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Stephens et al. 8,187,367 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Stephens et al. 8,187,367 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Brown et al. 8,187,367 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Brown et al. 8,187,367 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Brown et al. 8,187,367 B2 52012 Jaffe et al. 1,743,187 B2 6,2010 Brown et al. 8,203,203 B2 6,2012 Gregorich et al. 1,743,187 B2 6,2010 Guncar et al. 8,203,203 B2 7,2010 Jaffe et al. 8,203,203 B2 7,2010 Jaffe et al. 8,203,203 B2 7,2012 Jaffe et al. 1,243,243 B2 7,2010 Jaffe et al. 8,203,203 B2 7,2012 Jaffe et al. 1,243,243 B2 7,2010 Jaffe et al. 8,203,203 B2 7,2012 Jaffe e					
7.66,204 B2 2,2010 Thornton et al. \$1,48,778 B2 3,2012 Zaharia et al. 7.66,204 B2 3,2010 McGraw et al. \$1,48,877 B2 4,2012 Jange et al. \$1,90,50 B2 4,2012 Jange et al. \$1,71,757 B2 5,2012 Jange et al. \$1,71,757 B2 5,			8,133,269 B2	3/2012	Flechsenhar et al.
7,680,247 B2 3/2010 Arzinger et al. 359/344 7,684,991 B2 3/2010 Stohe et al. 359/344 7,711,413 B2 5/2010 Feldman et al. 8,167,932 B2 5/2012 Jaffare et al. 359/344 7,712,398 B2 6/2010 Lasker et al. 8,177,809 B2 5/2012 Jaffare et al. 7,736,317 B2 6/2010 Stophens et al. 8,187,809 B2 5/2012 Jaffare et al. 7,736,317 B2 6/2010 Stophens et al. 8,187,267 B2 5/2012 Jaffare et al. 7,736,317 B2 6/2010 Stophens et al. 8,187,267 B2 5/2012 Jaffare et al. 7,736,317 B2 6/2010 Brown et al. 8,187,267 B2 5/2012 Jaffare et al. 1,737,318 B2 6/2010 Brown et al. 8,187,267 B2 5/2012 Jaffare et al. 1,737,318 B2 6/2010 Brown et al. 8,187,267 B2 5/2012 Jaffare et al. 1,737,318 B2 6/2010 Brown et al. 8,187,267 B2 5/2012 Jaffare et al. 1,737,318 B2 6/2010 Brown et al. 8,200,205 B2 6/2010 Brown et al. 8,200,205 B2 6/2010 Brown et al. 8,200,205 B2 6/2010 Ware et al. 8,200,205 B2 6/2010 Jaffare et al. 8,200,205 B2 10/2010 Jaffare et					
359/344 7,724,725 7,724,					
7,711,418 B2 5/2010 Feldman et al. 8,167,932 B2 5/2012 Jaffee et al. 7,728,986 B2 6/2010 Lasker et al. 8,177,809 B2 5/2012 Jaffee et al. 8,187,267 B2 5/2012 Jaffee et al. 8,286,249 B2 6/2012 Geognich et al. 8,286,249 B2 6/2012 Geognich et al. 8,283,368 B2 6/2012 Geognich et al. 8,283,368 B2 7/2012 Wayar et al. 8,233,718 B2 7/2012 Alytward et al. 8,233,718 B2 7/2012 Alytward et al. 8,233,718 B2 7/2012 Jaffee et al. 8,234,248 B2 9/2012 Doit et al. 8,238,249 B2 2012 Doit et al. 8,238,249 B2 10,2012 Jaffee et al. 8,238,149 B2 10,2012 Jaffee et al. 8,238,249 B2 11,2012 Jaffee et al. 8,238,249 B2 11,2			6,145,505 DZ	7/2012	
7,720,322 B2 5,2010 Prisco					
7,734,009 B2 62010 Brunner et al. 7,734,078 B2 62010 Stophens et al. 7,736,178 B2 62010 Stophens et al. 8,187,878 B2 5/2012 Hu et al. 7,736,178 B2 62010 Brown et al. 8,187,878 B2 6/2012 Gegorich et al. 7,736,294 B2 7/2010 Kornkven Volk et al. 8,206,429 B2 6/2012 Gregorich et al. 7,737,392 B2 8/2010 Kornkven Volk et al. 8,202,906 B2 7/2012 Wyar et al. 7,773,792 B2 8/2010 Guracar et al. 8,233,368 B2 7/2012 Wyar et al. 7,773,793 B3 8/2010 Childers et al. 8,233,718 B2 7/2012 Klingensmith et al. 7,773,794 B2 8/2010 Childers et al. 8,233,718 B2 7/2012 Klingensmith et al. 7,783,337 B2 8/2010 Galle et al. 8,239,738 B2 8/2010 Diet al. 7,783,337 B2 8/2010 Galle et al. 8,239,738 B2 8/2010 Diet al. 7,783,437 B2 9/2010 Barbu et al. 8,230,740 B2 10/2012 Milner et al. 7,801,340 B2 9/2010 Unal et al. 8,230,748 B2 10/2012 Milner et al. 7,801,540 B2 10/2010 Peterssen et al. 8,239,149 B2 10/2012 Tearney et al. 7,831,041 B2 11/2010 Unal et al. 8,239,149 B2 10/2012 Tearney et al. 7,833,041 B2 11/2010 Sugg et al. 8,239,149 B2 10/2012 Hastings et al. 8,330,418 B2 11/2010 Sugg et al. 8,330,408 B2 11/2010 Suge et al. 8,330,408 B2 11/2010 Sugg et al. 8,330,408 B2 11/2011 Sugg et al. 8,340,408 B2 11/2013 Sugg et al. 8,340,	7,720,322 B2 5/2010				
7,736,317 B2 6,2010 Stephens et al. 8,187,267 B2 5/2012 Pappone et al. 7,742,795 B2 6/2010 Stone et al. 8,187,830 B2 5/2012 Hu et al. 7,743,189 B2 6/2010 Stone et al. 8,187,830 B2 6/2012 Ice et al. 7,766,896 B2 8,2010 Nix et al. 8,206,429 B2 6/2012 Teagney et al. 7,773,798 B2 8,2010 Kimmel et al. 8,223,681 B2 7/2012 Vayard et al. 7,773,981 B1 8,2010 Guracar et al. 8,233,681 B2 7/2012 Ayhward et al. 7,773,981 B1 8,2010 Guracar et al. 8,233,681 B2 7/2012 Ayhward et al. 7,773,798 B2 8,2010 Childers et al. 8,233,718 B2 8,2010 Childers et al. 8,233,681 B2 7/2012 Ayhward et al. 7,781,724 B2 8,2010 Childers et al. 8,233,681 B2 8,2012 Doi et al. 7,781,724 B2 8,2010 Galle et al. 8,233,681 B2 8,2012 Doi et al. 8,233,681 B2 8,2012 Doi et al. 8,233,681 B2 8,2012 Sineral et al. 8,277,386 B2 10,2012 Ahmed et al. 7,783,127 B2 9,2010 Galle et al. 8,277,386 B2 10,2012 Ahmed et al. 8,280,470 B2 9,2010 Unal et al. 8,280,470 B2 10,2012 Glynn et al. 8,280,470 B2 9,2010 Unal et al. 8,280,470 B2 10,2012 Glynn et al. 8,280,470 B2 10,2012 Glynn et al. 8,280,428 B2 10,2					
7,742,795 B2 6/2010 Stome et al. 7,743,795 B2 6/2010 Brown et al. 7,763,954 B2 7/2010 Nix et al. 7,763,954 B2 7/2010 Nix et al. 7,763,954 B2 7/2010 Kimken volk et al. 7,763,958 B1 8/2010 Gillo Grammer et al. 7,773,792 B2 8/2010 Gillo Grammer et al. 7,773,792 B2 8/2010 Eidenschink et al. 7,773,793 B1 8/2010 Gillo Grammer et al. 7,773,794 B2 8/2010 Eidenschink et al. 7,781,724 B2 8/2010 Eidenschink et al. 7,781,724 B2 8/2010 Eidenschink et al. 7,781,724 B2 8/2010 Feldman et al. 7,783,337 B2 8/2010 Feldman et al. 7,783,337 B2 8/2010 Feldman et al. 7,783,337 B2 8/2010 Galle et al. 7,783,337 B2 8/2010 Galle et al. 7,893,343 B2 9/2010 Brown et al. 8,280,284 B2 10/2012 Simeral et al. 7,801,343 B2 9/2010 Unal et al. 8,280,284 B2 10/2012 Gillo et al. 7,801,509 B2 10/2010 Petersen et al. 8,280,348 B2 10/2012 Gillo et al. 7,803,041 B2 10/2010 Petersen et al. 8,280,148 B2 10/2012 Feldman et al. 7,803,041 B2 11/2010 Other et al. 8,280,148 B2 10/2012 Haunder et al. 7,803,041 B2 11/2010 Other et al. 8,280,148 B2 10/2012 Haunder et al. 7,803,041 B2 11/2010 Other et al. 8,298,147 B2 10/2012 Haunder et al. 8,298,147 B2 10/2012 Haunder et al. 8,298,147 B2 10/2012 Lammerhint et al. 8,298,147 B2 10/2012 Lammerhint et al. 8,280,284 B2 11/2010 Other et al. 8,298,147 B2 10/2012 Lammerhint et al. 8,298,148 B2 11/2010 Saudat 8,320,033 B2 12/2010 Milner et al. 8,320,034 B2 12/2010 Saudat 8,320,035 B2 12/2011 Marin et al. 8,320,034 B2 12/2011 Saudat 8,320,035 B2 12/2011 Marin et al. 8,320,034 B2 12/2011 Marin et al. 8,320,035 B2 12/2011 Marin et al. 8,320,036 B2 12/2011 Marin et al. 8,320,038 B2 12/2011 M					
7.762.954 B2 7.2010 Nix et al. 7.762.954 B2 7.2010 Nix et al. 8.206.429 B2 6.2012 Gregorich et al. 7.763.792 B2 8.2010 Komkven Volk et al. 8.208.995 B2 7.2012 Wyar et al. 7.773.792 B2 8.2010 Komkven Volk et al. 8.223.906 B2 7.2012 Wyar et al. 7.773.793 B1 8.2010 Ginerac et al. 8.233.718 B2 7.2012 Wyar et al. 7.7773.793 B2 8.2010 Eidenschink et al. 8.233.718 B2 7.2012 Klingensmith et al. 7.787.737 B2 8.2010 Eidenschink et al. 8.233.718 B2 7.2012 Klingensmith et al. 7.787.127 B2 8.2010 Feldman et al. 8.233.718 B2 8.2010 Eidenschink et al. 8.233.874 B2 8.2010 Eidenschink et al. 8.239.874 B2 8.2010 Galle et al. 7.787.127 B2 8.2010 Galle et al. 8.289.874 B2 10.2012 Milner et al. 8.289.874 B2 10.2012 Milner et al. 7.801.930 B2 9.2010 Feldman et al. 8.289.874 B2 10.2012 Milner et al. 7.801.940 B2 9.2010 Feldman et al. 8.289.814 B2 10.2012 Fearney et al. 8.289.814 B2 10.2012 Huenneckens et al. 8.289.814 B2 10.2012 Huenneckens et al. 8.289.814 B2 10.2012 Huenneckens et al. 8.289.814 B2 10.2012 Elementerin et al. 8.298.149 B2 10.2012 Hastings et al. 8.298.149 B2 10.2012 Hastings et al. 8.289.814 B2 10.2012 Debrie et al. 8.304.282 B2 11.2012 Davics et al. 8.304.282 B2 11.2012 Davics et al. 8.305.638 B2 1.2011 Davics et al. 8.325.2013 B2 12.2011 Martin et al. 8.325.2013 B2 12.2011 Martin et al. 8.325.2013 B2 12.2011 Davics et al. 8.336.643 B2 12.2011 Martin et al. 8.359.948 B2 1.2011 Davics et al. 8.359.948 B2 1.2011 Davics et al. 8.359.948 B2 1.2011 Martin et al. 8.359.948 B2 1.20					
7,766,896 B2 82010 Kornkven Volk et al. 8,208,995 B2 6/2012 Tearney et al. 7,773,798 B3 82 B2 B2 B2 7,2012 Way et al. 7,775,981 B1 8/2010 Gurnaer et al. 8,233,081 B2 7,2012 Aylward et al. 7,775,981 B1 8/2010 Edonachink et al. 8,233,081 B2 7,2012 Aylward et al. 8,233,081 B2 8,2012 Doi et al. 8,233,081 B2 10,2010 Barbu et al. 8,283,232 B2 10,2012 Almed et al. 7,201,342 B2 9,2010 Eddman et al. 8,289,824 B2 10,2012 Edymer et al. 8,281,340 B2 10,2010 Federson et al. 8,288,147 B2 10,2012 Edymer et al. 8,281,409 B2 10,2010 Federson et al. 8,298,147 B2 10,2012 Huennekens et al. 8,281,409 B2 10,2010 Edymer et al. 8,298,149 B2 10,2012 Huennekens et al. 8,281,409 B2 10,2010 Dorder et al. 8,298,147 B2 10,2012 Sillard et al. 8,281,409 B2 11,2010 Dorder et al. 8,301,400 B2 12,2012 Davise et al. 8,282,814 B2 11,2012 Davise et al. 8,282,814 B2 12,2012 Martin et al. 8,282,814 B2 12,2013 Cai et al. 8,282,814 B2 1					
7,773,792 B2 8,2010 Kimmel et al. 8,222,906 B2 7/2012 Wyar et al. 7,773,793 B1 8,2010 Guracar et al. 8,233,718 B2 7/2012 Aylward et al. 7,771,7399 B2 8,2010 Guracar et al. 8,233,718 B2 7/2012 Aylward et al. 7,781,774 B2 8,2010 Glade et al. 8,238,624 B2 8,2012 Doi et al. 7,781,774 B2 8,2010 Glade et al. 8,239,938 B2 8/2012 Doi et al. 8,238,337 B2 8/2012 Doi et al. 8,239,378 B2 10/2012 Doi et al. 8,239,378 B2 10/2012 Miner et al. 8,239,378 B2 10/2012 Miner et al. 8,239,378 B2 10/2012 Glynn et al. 8,239,374 B2 10/2012 Glynn et al. 8,239,324 B2 10/2012 Glynn et al. 8,239,348 B2 10/2012 Glynn et al. 8,239,349 B2 10/2012 Glynn et al. 8,309,428 B2 11/2012 Glynn et al. 8,309,438 B2 11/2013 Glynn et al. 8,309,439,439 B2 11/2013 Glynn et al.					
7.775,981 B1 8/2010 Guracar et al. 8.233,081 B2 7/2012 Alytand et al. 7.775,981 B2 7/2012 Alytand et al. 8.233,081 B2 7/2012 Alytand et al. 7.781,172 B2 8/2010 Eidenschink et al. 8.238,624 B2 8/2012 Soineral et al. 7.783,172 B2 8/2010 Feldman et al. 8.273,736 B2 10/2012 Almeral et al. 7.783,172 B2 8/2010 Feldman et al. 8.273,736 B2 10/2012 Almeral et al. 7.792,342 B2 9/2010 Barbu et al. 8.289,284 B2 10/2012 Milner et al. 8.280,470 B2 10/2012 Milner et al. 8.280,147 B2 10/2012 Milner et al. 8.280,147 B2 10/2012 Almeral et al. 8.280,149 B2 10/2013 Almeral et al. 8.2			8,222,906 B2	7/2012	Wyar et al.
7781,724 82 82010 Childers et al. 8,238,624 82 82012 Soic et al. 7783,337 82 82010 Galle et al. 8,239,388 82 82012 Simeral et al. 7,787,127 82 82010 Galle et al. 8,239,470 82 10,2012 Milner et al. 7,787,127 82 82010 Galle et al. 8,289,284 82 10,2012 Milner et al. 7,801,343 82 92010 Unal et al. 8,289,284 82 10,2012 Milner et al. 7,801,590 82 10,2010 Petersen et al. 8,289,147 82 10,2012 Tearney et al. 7,813,690 82 10,2010 Petersen et al. 8,289,147 82 10,2012 Huennekens et al. 7,830,941 82 11,2010 Sing et al. 8,309,408 82 11,2012 Sillard et al. 7,831,104 82 12,2010 Otat et al. 8,309,428 82 11,2012 Davies et al. 7,853,316 82 12,2010 Milner et al. 8,323,201 82 12,2011 Martin et al. 7,862,595 82 12,2011 Davies et al. 8,336,643 82 12,2012 Martin et al. 7,877,759 82 17,011 Tearney et al. 8,339,45 82 12,2012 Martin et al. 7,880,868 82 2,2011 Brauker et al. 8,353,945 82 12,2013 Schreck 7,881,636 82 2,2011 Brauker et al. 8,353,945 82 12,2013 Schreck 7,890,844 82 3,2011 Alkharib et al. 8,353,945 82 12,2013 Martin et al. 7,921,784 82 4/2011 Hennings et al. 8,361,679 82 12,2013 Martin et al. 7,927,784 82 4/2011 Simpson 8,386,560 82 2,2011 Mart et al. 7,930,104 82 4/2011 Huennekens et al. 8,417,491 82 4,2013 Mas et al. 7,930,104 82 4/2011 Huennekens et al. 8,417,491 82 4,2013 Mas et al. 7,930,104 82 4/2011 Huennekens et al. 8,447,468 82 5,2013 Martin et al. 7,930,104 82 4/2011 Huennekens et al. 8,447,468 82 5,2013 Martin et al. 7,930,104 82 4/2011 Mas et al. 8,448,468 82 5,2013 Martin et al. 7,930,104 82 4/2011 Huennekens et al. 8,447,468 82 5,2013 Martin et al. 7,930,104 82 4/2011 Huennekens et al. 8,448,468	7,775,981 B1 8/2010				,
Record R					
7,787,127 B2 82,010 Galle et al. 8,277,386 B2 10,02012 Milner et al.					
7,992,342 B2 9/2010 Unal et al. 8,289,244 B2 10/2012 Glynn et al. 7,801,590 B2 9/2010 Unal et al. 8,289,522 B2 10/2012 Glynn et al. 7,813,650 B2 10/2012 Feldman et al. 8,289,522 B2 10/2012 Glynn et al. 10/2012 Glynn et al. 7,813,609 B2 10/2012 Feldman et al. 8,289,147 B2 10/2012 Huenneckens et al. 10/2012 Harlman et al. 11/2012 Davice et al. 11/2012 Davice et al. 11/2012 Davice et al. 11/2012 Huennechirt et al. 11/2012 Hue			8,277,386 B2		
7,801,590 B2	7,792,342 B2 9/2010				
Petersen et al. Sept. Petersen et al.				10/2012	Tearney et al.
7,830,941 B2 11/2010 Sugg et al. 8,298,149 B2 10/2012 Silitard et al. 7,381,081 B2 11/2010 Li 8,301,000 B2 10/2012 Silitard et al. 7,3846,101 B2 12/2010 Obta et al. 8,309,428 B2 11/2012 Lemmerhirt et al. 7,3853,104 B2 12/2010 Milner et al. 8,317,713 B2 12/2010 Towfiner et al. 8,323,201 B2 12/2012 Towfiner et al. 7,380,555 B2 12/2010 Saadat 8,329,033 B2 12/2012 Towfiner et al. 8,336,643 B2 12/2011 Divaise et al. 8,336,643 B2 12/2011 Tearney et al. 8,336,643 B2 12/2012 Martin et al. 12/2014 Martin et al. 12/2015 Martin et al. 12/2016 Martin et al. 12/2018 Martin et al. 12/2019 Martin et al					
7,846,101 B2 12/2010 Eberle et al. 8,309,428 B2 11/2012 Lemmerhirt et al.					
7,853,104 B2 12/2010 Oota et al. 8,317,713 B2 11/2012 Davies et al. 7,853,316 B2 12/2010 Miner et al. 8,323,201 B2 12/2012 Towfiq et al. 8,323,0555 B2 12/2012 Martin et al. 1,2012 Rateman Park 1,2013 Rate al. 1,2014 Rateman Park 1,2014 Rateman Park 1,2015 Rateman Park 1,2015 Rateman Park 1,2016 Rateman Park 1,2016 Rateman Park 1,2017 Rateman Park 1,2018 Rateman Park 1,2018 Rateman Park 1,2019 Rateman Pa					
7,853,316 B2 12/2010 Saadat 8,323,203 B2 12/2012 Martin et al. 7,860,555 B2 1/2011 Davies et al. 8,336,643 B2 12/2012 Martin et al. 7,872,759 B2 1/2011 Tearney et al. 8,349,000 B2 1/2013 Andreas et al. 7,881,763 B2 2/2011 Aoki 8,353,945 B2 1/2013 Andreas et al. 7,909,848 B2 2/2011 Bauker et al. 8,361,097 B2 1/2013 Martin et al. 7,921,854 B2 4/2011 Hennings et al. 8,361,097 B2 1/2013 Martin et al. 7,927,784 B2 4/2011 Kimpings et al. 8,361,097 B2 1/2013 Maet et al. 7,930,104 B2 4/2011 Hunenkens et al. 8,412,312 B2 4/2013 Maet et al. 7,930,104 B2 4/2011 Baker et al. 8,417,491 B2 4/2013 Invota et al. 7,942,852 <					
7,805,508 B2 1/2011 Davies et al. 8,336,643 B2 1/2012 Harleman 7,872,759 B2 1/2011 Tearney et al. 8,349,000 B2 1/2013 Schreck 7,880,868 B2 2/2011 Aoki 8,353,945 B2 1/2013 Andreas et al. 7,881,763 B2 2/2011 Brauker et al. 8,353,945 B2 1/2013 Cai et al. 7,909,844 B2 3/2011 Alkhatib et al. 8,357,981 B2 1/2013 Martin et al. 7,927,784 B2 4/2011 Hennings et al. 8,361,079 B2 1/2013 Patel et al. 7,927,784 B2 4/2011 Kemp 8,398,591 B2 2/2013 Mas et al. 7,920,148 B2 4/2011 Huennekens et al. 8,412,312 B2 4/2013 Judell et al. 7,930,104 B2 4/2011 Baker et al. 8,412,312 B2 4/2013 Judell et al. 7,930,104 B2 4/2011 Jiang et al. 8,414,491 B2 4/2013 Judell et al. 7,936,462 B2 5/2011 Jiang et al. 8,445,4685 B2 6/2013 Nair et al. 7,947,012 B2 5/2011 Spurchise et al. 8,454,685 B2 6/2013 Alkhatib 7,949,029 B2 5/2011 Spurchise et al. 8,475,522 B2 7/2013 Jimenez et al. 7,951,186 B2 5/2011 Brennan, III 8,486,063 B2 7/2013 Belhe et al. 7,977,950 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Belhe et al. 7,977,950 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,978,916 B2 7/2011 Maslen 8,500,798 B2 8/2011 Crall Rowe 8,550,798 B2 8/2011 Feldman et al. 8,597,349 B2 1/2013 Beyar et al. 7,998,333 B2 8/2011 Trofimov et al. 8,600,477 B2 11/2013 Beyar et al. 7,999,333 B2 8/2011 Trofimov et al. 8,600,077 B2 11/2013 Beyar et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 1/2/2013 Barratt et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 1/2/2013 Barratt et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 1/2/2013 Barratt et al. 8,031,373 B2 9/2011 Dolan 8,662,055 B2 1/2/2013 Barratt et al. 8,031,373 B2 9/2011 Dolan 8,662,055 B2 1/2/2013 Rarratt et al. 8,031,373 B2 1/2/2011 Milner 8,664,910 B2 2/2/2014 Rousso et al.					
7,872,759 B2					
7,880,868 B2 2/2011 Aoki 8,353,945 B2 1/2013 Andreas et al. 7,881,763 B2 2/2011 Brauker et al. 8,353,954 B2 1/2013 Cai et al. 1,909,844 B2 3/2011 Alkhatib et al. 8,357,981 B2 1/2013 Martin et al. 1,921,854 B2 4/2011 Hennings et al. 8,361,097 B2 1/2013 Patel et al. 1,921,854 B2 4/2011 Simpson 8,386,560 B2 2/2013 Ma et al. 1,921,48 B2 4/2011 Kemp 8,398,591 B2 3/2013 Mas et al. 1,930,104 B2 4/2011 Baker et al. 8,412,312 B2 4/2013 Judell et al. 1,930,104 B2 4/2011 Jiang et al. 8,417,491 B2 4/2013 Trovato et al. 1,930,104 B2 4/2011 Baker et al. 8,449,465 B2 5/2013 Nair et al. 1,942,852 B2 5/2011 Mas et al. 8,449,465 B2 5/2013 Nair et al. 1,942,852 B2 5/2011 Spurchise et al. 8,454,688 B2 6/2013 Hariton et al. 1,947,012 B2 5/2011 Sugg et al. 8,454,686 B2 6/2013 Alkhatib Nair et al. 1,951,186 B2 5/2011 Eidenschink et al. 8,478,384 B2 7/2013 Schmitt et al. 1,951,186 B2 5/2011 Brennan, III 8,486,063 B2 7/2013 Schmitt et al. 1,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 1,977,950 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 1,9797,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Condit et al. 1,998,164 B2 7/2011 McGahan 8,51,676 B2 9/2013 Shou 1,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 1,998,333 B2 8/2011 Oral et al. 8,500,477 B2 12/2013 Beyar et al. 1,999,333 B2 8/2011 Oral et al. 8,500,477 B2 12/2013 Beyar et al. 1,999,333 B2 8/2011 Oral et al. 8,600,477 B2 12/2013 Beyar et al. 1,999,338 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 1,999,338 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 1,999,338 B2 8/2011 Dolan 8,600,56 B2 12/2013 Barratt et al. 8,021,470 B2 9/2011 Milner 8,644,910 B2 2/2014 Rows et al. 8,031,470 B2 2/2014 Milner 4. 8,601,056 B2 12/2013 Barratt et al. 8,021,470 B2 9/2011 Dolan 8,600,056 B2 12/2013 Barratt et al. 8,031,470 B2 1					
7,881,763 B2 2/2011 Brauker et al. 8,353,954 B2 1/2013 Cai et al. 7,909,844 B2 3/2011 Alkhatib et al. 8,357,981 B2 1/2013 Martin et al. 7,921,854 B2 4/2011 Hennings et al. 8,366,60 B2 2/2013 Ma et al. 7,929,148 B2 4/2011 Kemp 8,398,591 B2 3/2013 Mas et al. 7,930,104 B2 4/2011 Huennekens et al. 8,417,491 B2 4/2013 Irovato et al. 7,930,104 B2 4/2011 Baker et al. 8,417,491 B2 4/2013 Irovato et al. 7,930,406 B2 5/2011 Baker et al. 8,449,465 B2 5/2011 Nair et al. 7,942,852 B2 5/2011 Spurchise et al. 8,454,686 B2 6/2013 Alkhatib 7,949,029 B2 5/2011 Spurchise et al. 8,475,522 B2 7/2013 Jimmenz et al. 7,951,186			8,353,945 B2	1/2013	Andreas et al.
7,921,854 B2 4/2011 Hennings et al. 8,361,097 B2 1/2013 Patel et al. 2/2017,784 B2 4/2011 Simpson 8,386,560 B2 2/2013 Ma et al. 7,929,148 B2 4/2011 Huennekens et al. 8,412,312 B2 4/2013 Judell et al. 7,930,014 B2 4/2011 Baker et al. 8,417,491 B2 4/2013 Trovato et al. 7,930,104 B2 4/2011 Baker et al. 8,417,491 B2 4/2013 Trovato et al. 7,936,462 B2 5/2011 Jiang et al. 8,449,465 B2 5/2013 Nair et al. 7,947,012 B2 5/2011 Spurchise et al. 8,454,685 B2 6/2013 Hariton et al. 8,454,685 B2 6/2013 Hariton et al. 8,454,685 B2 6/2013 Hariton et al. 7,947,012 B2 5/2011 Spurchise et al. 8,478,384 B2 7/2013 Simenez et al. 8,478,384 B2 7/2013 Schmitt et al. 8,478,384 B2 7/2013 Schmitt et al. 7,951,186 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Selhe et al. 7,972,353 B2 7/2011 Hendriksen et al. 8,486,063 B2 7/2013 Magnin et al. 7,976,492 B2 7/2011 Brauker et al. 8,486,063 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 Klingensmith et al. 8,531,676 B2 9/2013 Condit et al. 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Shou 7,981,151 B2 7/2011 Feldman et al. 8,597,378 B2 11/2013 Bepart et al. 7,993,333 B2 8/2011 Trofimov et al. 8,597,378 B2 11/2013 Bepart et al. 7,995,060 B2 8/2011 Trofimov et al. 8,600,477 B2 12/2013 Lauwers et al. 7,999,938 B2 8/2011 Trofimov et al. 8,600,477 B2 12/2013 Beyar et al. 8,021,470 B2 9/2011 Eskuri 8,601,056 B2 12/2013 Barratt et al. 8,021,470 B2 9/2011 Milner 8,604,910 B2 2/2014 Rowse et al. 8,021,470 B2 9/2011 Milner 8,604,910 B2 2/2014 Rowse et al. 8,021,470 B2 9/2011 Milner 8,604,910 B2 2/2014 Rowse et al. 8,021,470 B2 9/2011 Milner 8,604,910 B2 2/2014 Rowse et al.	7,881,763 B2 2/2011	Brauker et al.			
7,927,784 B2 4/2011 Simpson 8,386,560 B2 2/2013 Ma et al. 7,929,148 B2 4/2011 Huennekens et al. 7,930,104 B2 4/2011 Baker et al. 8,412,312 B2 4/2013 Trovato et al. 7,930,104 B2 4/2011 Jiang et al. 8,417,491 B2 4/2013 Nair et al. 7,936,462 B2 5/2011 Jiang et al. 8,449,465 B2 5/2013 Nair et al. 7,942,852 B2 5/2011 Mas et al. 8,454,686 B2 6/2013 Alkhatib 7,947,012 B2 5/2011 Spurchise et al. 8,454,686 B2 6/2013 Alkhatib 7,949,029 B2 5/2011 Eidenschink et al. 8,475,522 B2 7/2013 Schmitt et al. 7,952,719 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Schmitt et al. 7,972,353 B2 7/2011 Brauker et al. 8,486,063 B2 7/2013 Behe et al. 7,977,950 B2 7/2011 Brauker et al. 8,486,063 B2 7/2013 Ma et al. 8,491,567 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 McGahan 8,500,798 B2 8/2013 Shou 7,981,041 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,995,210 B2 8/2011 Tearney et al. 8,597,349 B2 12/2013 Boppart et al. 8,599,333 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 8,021,377 B2 9/2011 Eskuri 8,601,568 B2 12/2013 Barrat et al. 8,021,377 B2 9/2011 Dolan 8,602,055 B2 12/2013 Barrat et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rowso et al.					
7,929,148 B2 4/2011 Kemp 8,398,591 B2 3/2013 Mas et al. 7,930,014 B2 4/2011 Huennekens et al. 8,412,312 B2 4/2013 Trovato et al. 7,930,104 B2 4/2011 Baker et al. 8,417,491 B2 4/2013 Trovato et al. 7,936,462 B2 5/2011 Jiang et al. 8,449,465 B2 5/2013 Nair et al. 7,942,852 B2 5/2011 Mas et al. 8,454,686 B2 6/2013 Hariton et al. 7,947,012 B2 5/2011 Spurchise et al. 8,475,522 B2 7/2013 Jimenez et al. 7,949,029 B2 5/2011 Eidenschink et al. 8,478,384 B2 7/2013 Schmitt et al. 7,951,186 B2 5/2011 Brennan, III 8,486,063 B2 7/2013 Werneth et al. 7,972,353 B2 7/2011 Hendriksen et al. 8,486,063 B2 7/2013 Werneth et al. 7,976,492 B2 7/2011 Maslen 8,500,788 B2 8/2013 Rowe et al. 7,977,950 B2 7/2011 Maslen 8,500,788 B2 8/2013 Rowe et al. 7,981,041 B2 7/2011 Rowe 8,531,676 B2 9/2013 Shou 7,983,737 B2 7/2011 Rowe 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Trofimov et al. 8,600,477 B2 12/2013 Beyar et al.					
7,930,104 B2 4/2011 Baker et al. 7,936,462 B2 5/2011 Jiang et al. 8,449,465 B2 5/2013 Nair et al. 7,942,852 B2 5/2011 Mas et al. 8,449,465 B2 5/2013 Hariton et al. 7,947,012 B2 5/2011 Spurchise et al. 8,454,686 B2 6/2013 Hariton et al. 7,947,012 B2 5/2011 Sugg et al. 8,475,522 B2 7/2013 Jimenez et al. 7,951,186 B2 5/2011 Biedenschink et al. 8,478,384 B2 7/2013 Schmitt et al. 7,952,719 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Belhe et al. 7,972,353 B2 7/2011 Hendriksen et al. 8,491,567 B2 7/2013 Werneth et al. 7,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 Klingensmith et al. 8,531,676 B2 9/2013 Schmitt et al. 7,981,041 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,597,349 B2 12/2013 Bepart et al. 8,597,349 B2 12/2013 Bepart et al. 8,600,477 B2 12/2013 Bepart et al. 8,600,477 B2 12/2013 Bepart et al. 8,601,378 B2 9/2011 Eskuri 8,601,056 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.	7,929,148 B2 4/2011				
7,936,462 B2 5/2011 Jiang et al. 8,449,465 B2 5/2013 Nair et al. 7,942,852 B2 5/2011 Mas et al. 8,454,686 B2 6/2013 Hariton et al. 7,947,012 B2 5/2011 Spurchise et al. 8,454,686 B2 6/2013 Jimenez et al. 8,454,686 B2 7/2013 Jimenez et al. 8,478,384 B2 7/2013 Jimenez et al. 7,951,186 B2 5/2011 Eidenschink et al. 8,478,384 B2 7/2013 Schmitt et al. 7,952,719 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Belhe et al. 7,972,353 B2 7/2011 Hendriksen et al. 8,486,063 B2 7/2013 Werneth et al. 7,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 Klingensmith et al. 8,531,676 B2 9/2013 Condit et al. 7,981,041 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,999,938 B2 8/2011 Trofimov et al. 8,600,477 B2 12/2013 Schimert et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,942,852 B2 5/2011 Mas et al. 7,947,012 B2 5/2011 Spurchise et al. 7,949,029 B2 5/2011 Sugg et al. 7,951,186 B2 5/2011 Eidenschink et al. 7,952,719 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Schmitt et al. 7,972,353 B2 7/2011 Brennan, III 8,486,063 B2 7/2013 Werneth et al. 7,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Werneth et al. 7,977,950 B2 7/2011 Maslen 8,590,798 B2 8/2013 Rowe et al. 7,981,041 B2 7/2011 Klingensmith et al. 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Shou 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,995,210 B2 8/2011 Oral et al. 8,594,757 B2 11/2013 Boppart et al. 8,597,349 B2 12/2013 Beyar et al. 8,600,917 B1 12/2013 Schimert et al. 8,600,917 B1 12/2013 Schimert et al. 8,601,056 B2 12/2013 Lauwers et al. 8,601,056 B2 12/2013 Barratt et al. 8,021,377 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner					
7,949,029 B2 5/2011 Sugg et al. 8,475,522 B2 7/2013 Jimenez et al. 7,951,186 B2 5/2011 Eidenschink et al. 8,486,062 B2 7/2013 Belhe et al. 7,972,353 B2 7/2011 Hendriksen et al. 8,486,063 B2 7/2013 Werneth et al. 7,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 Klingensmith et al. 8,531,676 B2 9/2013 Condit et al. 7,981,041 B2 7/2011 Rowe 8,550,911 B2 10/2013 Shou 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Tearney et al. 8,594,757 B2 11/2013 Boppart et al. 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Schimert et al. 7,999,938 B2 8/2011 Trofimov et al. 8,600,477 B2 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,600,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,951,186 B2 5/2011 Eidenschink et al. 7,952,719 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Belhe et al. 7,972,353 B2 7/2011 Hendriksen et al. 7,976,492 B2 7/2011 Brauker et al. 8,486,063 B2 7/2013 Werneth et al. 7,977,950 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,978,916 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,981,041 B2 7/2011 McGahan 8,537,865 B1 9/2013 Shou 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 7,993,333 B2 8/2011 Oral et al. 8,594,757 B2 11/2013 Boppart et al. 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Barratt et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner					
7,952,719 B2 5/2011 Brennan, III 8,486,062 B2 7/2013 Belhe et al. 7,972,353 B2 7/2011 Hendriksen et al. 7,976,492 B2 7/2011 Brauker et al. 8,491,567 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 Klingensmith et al. 7,981,041 B2 7/2011 Rowe 8,550,911 B2 10/2013 Shou 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 7,993,333 B2 8/2011 Oral et al. 8,594,757 B2 11/2013 Bepart et al. 8,594,757 B2 11/2013 Bepart et al. 8,594,757 B2 11/2013 Bepart et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,917 B1 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Lauwers et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,972,353 B2 7/2011 Hendriksen et al. 7,976,492 B2 7/2011 Brauker et al. 8,486,063 B2 7/2013 Magnin et al. 7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 8,531,676 B2 9/2013 Condit et al. 7,978,916 B2 7/2011 McGahan 8,537,865 B1 9/2013 Shou 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Lauwers et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.			8,486,062 B2	7/2013	Belhe et al.
7,977,950 B2 7/2011 Maslen 8,500,798 B2 8/2013 Rowe et al. 7,978,916 B2 7/2011 Klingensmith et al. 7,981,041 B2 7/2011 McGahan 8,531,676 B2 9/2013 Shou 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,477 B2 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.	7,972,353 B2 7/2011	Hendriksen et al.			
7,978,916 B2 7/2011 Klingensmith et al. 8,531,676 B2 9/2013 Condit et al. 7,981,041 B2 7/2011 McGahan 8,537,865 B1 9/2013 Shou 7,981,151 B2 7/2011 Rowe 8,550,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,981,041 B2 7/2011 McGahan 8,537,865 B1 9/2013 Shou 7,981,151 B2 7/2011 Rowe 8,559,911 B2 10/2013 Sylla 7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al. <td></td> <td></td> <td></td> <td></td> <td></td>					
7,983,737 B2 7/2011 Feldman et al. 8,594,757 B2 11/2013 Boppart et al. 7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 12/2013 Beyar et al. 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,993,333 B2 8/2011 Oral et al. 8,597,349 B2 12/2013 Alkhatib 7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Beyar et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,995,210 B2 8/2011 Tearney et al. 8,600,477 B2 12/2013 Beyar et al. 7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
7,996,060 B2 8/2011 Trofimov et al. 8,600,917 B1 12/2013 Schimert et al. 7,999,938 B2 8/2011 Wang 8,601,056 B2 12/2013 Lauwers et al. 8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
8,021,377 B2 9/2011 Eskuri 8,611,383 B2 12/2013 Govorkov et al. 8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.	7,996,060 B2 8/2011	Trofimov et al.	8,600,917 B1	12/2013	Schimert et al.
8,021,420 B2 9/2011 Dolan 8,620,055 B2 12/2013 Barratt et al. 8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					
8,036,732 B2 10/2011 Milner 8,644,910 B2 2/2014 Rousso et al.					

US 9,478,940 B2

Page 6

(56)	Referer	nces Cited	2005/0101859 A1	5/2005	Maschke	
, ,			2005/0113685 A1*		Maschke	A61B 5/0066 600/427
0.5.	PATENT	DOCUMENTS	2005/0140582 A1		Lee et al.	
2001/0013965 A1*	8/2001	Watanabe G02F 1/3511	2005/0140682 A1 2005/0140981 A1	6/2005 6/2005	Sumanaweera et al. Waelti	
2001/0029337 A1	10/2001	398/147 Pantages et al.	2005/0140984 A1	6/2005	Hitzenberger	
2001/0037073 A1	11/2001	White et al.	2005/0147303 A1		Zhou et al. Weber et al.	
2001/0046345 A1 2001/0049548 A1		Snyder et al. Vardi et al.	2005/0165439 A1 2005/0171433 A1		Boppart et al.	
2001/0049348 A1 2002/0034276 A1		Hu et al.	2005/0171438 A1	8/2005	Chen et al.	
2002/0041723 A1		Ronnekleiv et al.	2005/0182297 A1 2005/0196028 A1		Gravenstein et al. Kleen et al.	
2002/0067540 A1* 2002/0069676 A1		Delprat et al	2005/0190028 AT 2005/0197585 AT		Brockway et al.	
2002/0009070 A1 2002/0089335 A1		Williams	2005/0213103 A1	9/2005	Everett et al.	
2002/0099289 A1		Crowley	2005/0215942 A1 2005/0234445 A1	9/2005	Abrahamson et al. Conquergood et al.	
2002/0163646 A1 2002/0186818 A1		Anderson Arnaud et al.	2005/0243322 A1		Lasker et al.	
2002/0196446 A1	12/2002	Roth et al.	2005/0249391 A1		Kimmel et al.	ACID 5/0066
2002/0197456 A1	12/2002		2005/0251116 A1*	11/2005	Steinke	A01B 5/0000 606/8
2003/0004412 A1 2003/0016604 A1		Izatt et al. Hanes	2005/0251567 A1		Ballew et al.	000,0
2003/0018273 A1		Corl et al.	2005/0254059 A1		Alphonse	4.61D 5/0066
2003/0023153 A1 2003/0032886 A1		Izatt et al. Dgany et al.	2005/0254060 A1*	11/2003	Alphonse	356/479
2003/0052880 A1 2003/0050871 A1		Broughton	2005/0254061 A1*	11/2005	Alphonse	A61B 5/0066
2003/0065371 A1	4/2003	Satake	2005/0264823 A1	12/2005	Zhu et al.	356/479
2003/0069723 A1 2003/0077043 A1		Hegde Hamm et al.	2005/0204825 A1 2006/0013523 A1		Childlers et al.	
2003/007/045 A1 2003/0085635 A1	5/2003	Davidsen	2006/0015126 A1	1/2006		
2003/0090753 A1		Takeyama et al.	2006/0029634 A1 2006/0036167 A1	2/2006 2/2006	Berg et al.	
2003/0092995 A1 2003/0093059 A1		Thompson Griffin et al.	2006/0038115 A1	2/2006		
2003/0103212 A1		Westphal et al.	2006/0039004 A1		de Boer et al.	
2003/0152259 A1		Belykh et al.	2006/0041180 A1 2006/0045536 A1		Viswanathan et al. Arahira	
2003/0169785 A1* 2003/0181802 A1		Kim 372/20 Ogawa	2006/0055936 A1	3/2006	Yun et al.	
2003/0187369 A1	10/2003	Lewis et al.	2006/0058622 A1*	3/2006	Tearney	
2003/0194165 A1		Silberberg et al.	2006/0064009 A1	3/2006	Webler et al.	600/407
2003/0195419 A1 2003/0208116 A1		Harada Liang et al.	2006/0067620 A1		Shishkov et al.	
2003/0212491 A1	11/2003	Mitchell et al.	2006/0072808 A1		Grimm et al.	
2003/0219202 A1 2003/0220749 A1		Loeb et al. Chen et al.	2006/0074442 A1 2006/0098927 A1		Noriega et al. Schmidt et al.	
2003/0228039 A1	12/2003		2006/0100694 A1		Globerman	
2004/0015065 A1		Panescu et al.	2006/0106375 A1 2006/0132790 A1	5/2006 6/2006	Werneth et al.	
2004/0023317 A1 2004/0028333 A1		Motamedi et al. Lomas	2006/0132790 A1 2006/0135870 A1		Webler	
2004/0037742 A1		Jen et al.	2006/0142703 A1		Carter et al.	
2004/0042066 A1		Kinoshita et al.	2006/0142733 A1 2006/0173299 A1	8/2006	Forsberg Romley et al.	
2004/0054287 A1 2004/0067000 A1	3/2004 4/2004	Stephens Bates et al.	2006/0179255 A1		Yamazaki	
2004/0068161 A1	4/2004	Couvillon	2006/0184048 A1		Saadat	
2004/0082844 A1 2004/0092830 A1		Vardi et al. Scott et al.	2006/0187537 A1 2006/0195269 A1		Huber et al. Yeatman et al.	
2004/0092830 A1 2004/0106853 A1		Moriyama	2006/0204119 A1	9/2006	Feng et al.	
2004/0111552 A1		Arimilli et al.	2006/0229591 A1 2006/0239312 A1	10/2006	Lee Kewitsch et al.	
2004/0126048 A1 2004/0143160 A1		Dave et al. Couvillon	2006/0239312 A1 2006/0241342 A1		Macaulay et al.	
2004/0146546 A1		Gravett et al.	2006/0241465 A1		Huennekens et al.	
2004/0162487 A1*	8/2004	Klingenbeck-Regn A61B 5/0066	2006/0241503 A1 2006/0244973 A1		Schmitt et al. Yun et al.	
		600/427	2006/0258895 A1		Maschke	
2004/0186369 A1	9/2004		2006/0264743 A1		Kleen et al.	
2004/0186558 A1		Pavenik et al.	2006/0267756 A1 2006/0270976 A1	11/2006	Savage et al.	
2004/0195512 A1 2004/0220606 A1		Crosetto Goshgarian	2006/0276709 A1	12/2006	Khamene et al.	
2004/0225220 A1	11/2004	Rich	2006/0279742 A1 2006/0279743 A1		Tearney et al. Boesser et al.	
2004/0239938 A1	12/2004		2006/02/9/43 A1 2006/0285638 A1		Boese et al.	
2004/0242990 A1 2004/0246567 A1*		Brister et al. Ahn et al	2006/0287595 A1	12/2006	Maschke	
2004/0248439 A1	12/2004	Gernhardt et al.	2006/0293597 A1		Johnson et al.	
2004/0260236 A1 2005/0013778 A1		Manning et al. Green et al.	2007/0015969 A1 2007/0016029 A1		Feldman et al. Donaldson et al.	
2005/0013778 A1 2005/0031176 A1		Hertel et al.	2007/0016029 A1 2007/0016034 A1		Donaldson Donaldson	
2005/0036150 A1		Izatt et al.	2007/0016062 A1		Park et al.	
2005/0047727 A1*	3/2005	Shin H01S 5/0265	2007/0027390 A1		Maschke et al.	
2005/0078317 A1	4/2005	385/88 Law et al.	2007/0036417 A1 2007/0038061 A1		Argiro et al. Huennekens et al.	

(56)	Referen	nces Cited	2008/0187201 A1		Liang et al.
U.S.	PATENT	DOCUMENTS	2008/0228086 A1 2008/0247622 A1	10/2008	Ilegbusi et al. Aylward et al.
0.0.			2008/0247716 A1		Thomas et al.
2007/0038121 A1	2/2007	Feldman et al.	2008/0262470 A1		Lee et al.
2007/0038125 A1		Kleen et al.	2008/0262489 A1 2008/0269599 A1	10/2008	Csavoy et al.
2007/0043292 A1 2007/0043597 A1		Camus et al. Donaldson	2008/0209399 A1 2008/0281205 A1		Naghavi et al.
2007/0049397 A1 2007/0049847 A1		Osborne	2008/0281248 A1		Angheloiu et al.
2007/0060973 A1		Ludvig et al.	2008/0285043 A1		Fercher et al.
2007/0065077 A1		Childers et al.	2008/0287795 A1 2008/0291463 A1		Klingensmith et al. Milner et al.
2007/0066888 A1 2007/0066890 A1		Maschke Maschke	2008/0291403 A1 2008/0292173 A1		Hsieh et al.
2007/0000890 A1 2007/0066983 A1		Maschke	2008/0294034 A1		Krueger et al.
2007/0084995 A1		Newton et al.	2008/0298655 A1		Edwards
2007/0100226 A1		Yankelevitz et al.	2008/0306766 A1 2009/0009801 A1	1/2008	Ozeki et al. Tabuki
2007/0135887 A1 2007/0142707 A1		Maschke Wiklof et al.	2009/0009801 A1 2009/0018393 A1		Dick et al.
2007/0156019 A1		Larkin et al.	2009/0034813 A1		Dikmen et al.
2007/0161893 A1		Milner et al.	2009/0043191 A1		Castella et al.
2007/0161896 A1		Adachi et al.	2009/0046295 A1 2009/0052614 A1		Kemp et al. Hempel et al.
2007/0161963 A1 2007/0162860 A1		Smalling Muralidharan et al.	2009/0069843 A1		Agnew
2007/0165141 A1		Srinivas et al.	2009/0079993 A1		Yatagai et al.
2007/0167710 A1		Unal et al.	2009/0088650 A1 2009/0093980 A1	4/2009	Corl Kemp et al.
2007/0167804 A1 2007/0191682 A1		Park et al. Rolland et al.	2009/0093980 A1 2009/0122320 A1		Petersen et al.
2007/0191082 A1 2007/0201736 A1		Klingensmith et al.	2009/0138544 A1	5/2009	
2007/0206193 A1		Pesach	2009/0149739 A9		Maschke
2007/0208276 A1		Kornkven Volk et al.	2009/0156941 A1 2009/0174886 A1	6/2009 7/2009	
2007/0225220 A1 2007/0225590 A1		Ming et al. Ramos	2009/0174931 A1		Huber et al.
2007/0229801 A1		Tearney et al.	2009/0177090 A1		Grunwald et al.
2007/0232872 A1	10/2007	Prough et al.	2009/0177183 A1		Pinkernell et al.
2007/0232874 A1	10/2007 10/2007		2009/0195514 A1 2009/0196470 A1		Glynn et al. Carl et al.
2007/0232890 A1 2007/0232891 A1	10/2007		2009/0198125 A1		Nakabayashi et al.
2007/0232892 A1	10/2007		2009/0203991 A1		Papaioannou et al.
2007/0232893 A1		Tanioka	2009/0264768 A1 2009/0269014 A1	10/2009	Courtney et al. Winberg et al.
2007/0232933 A1 2007/0238957 A1	10/2007	Gille et al. Vared	2009/0270695 A1		Mceowen
2007/0247033 A1		Eidenschink et al.	2009/0284322 A1		Harrison et al.
2007/0250000 A1		Magnin et al.	2009/0284332 A1 2009/0284749 A1	11/2009 11/2009	Moore et al. Johnson et al.
2007/0250036 A1 2007/0258094 A1		Volk et al. Izatt et al.	2009/0294749 A1 2009/0290167 A1		Flanders et al.
2007/0258034 A1 2007/0260138 A1		Feldman et al.	2009/0292048 A1	11/2009	Li et al.
2007/0278389 A1	12/2007	30	2009/0299195 A1		Muller et al.
2007/0287914 A1 2008/0002183 A1	1/2007		2009/0299284 A1 2009/0318951 A1	12/2009 12/2009	Holman et al. Kashkarov et al.
2008/0002183 A1 2008/0013093 A1		Yatagai et al. Izatt et al.	2009/0326634 A1	12/2009	Vardi
2008/0021275 A1	1/2008	Tearney et al.	2010/0007669 A1		Bethune et al.
2008/0027481 A1		Gilson et al.	2010/0030042 A1 2010/0061611 A1		Denninghoff et al. Xu et al.
2008/0037108 A1*	2/2008	Yokoyama G02F 1/383 359/328	2010/0061611 A1 2010/0063400 A1		Hall et al.
2008/0043024 A1	2/2008	Schiwietz et al.	2010/0087732 A1		Eberle et al.
2008/0045842 A1		Furnish	2010/0094125 A1		Younge et al.
2008/0051660 A1 2008/0063304 A1		Kakadaris et al. Russak et al.	2010/0094127 A1 2010/0094135 A1	4/2010 4/2010	Fang-Yen et al.
2008/0085041 A1		Breeuwer	2010/0094143 A1	4/2010	Mahapatra et al.
2008/0095465 A1	4/2008	Mullick et al.	2010/0113919 A1		Maschke
2008/0095714 A1		Castella et al.	2010/0125238 A1 2010/0125268 A1		Lye et al. Gustus et al.
2008/0097194 A1 2008/0101667 A1		Milner Begelman et al.	2010/0125648 A1		Zaharia et al.
2008/0108867 A1	5/2008		2010/0128348 A1		Taverner
2008/0114254 A1		Matcovitch et al.	2010/0152717 A1 2010/0160788 A1	6/2010	Keeler Davies et al.
2008/0119739 A1 2008/0124495 A1		Vardi et al. Horn et al.	2010/0161023 A1		Cohen et al.
2008/0125772 A1		Stone et al.	2010/0168714 A1		Burke et al.
2008/0139897 A1	6/2008	Ainsworth et al.	2010/0179421 A1	7/2010	
2008/0143707 A1		Mitchell	2010/0179426 A1 2010/0220334 A1		Davies et al. Condit et al.
2008/0146941 A1 2008/0147111 A1		Dala-Krishna Johnson et al.	2010/0226607 A1		Zhang et al.
2008/0154128 A1		Milner	2010/0234736 A1	9/2010	Corl
2008/0161696 A1		Schmitt et al.	2010/0249601 A1		Courtney
2008/0171944 A1		Brenneman et al.	2010/0256616 A1 2010/0272432 A1		Katoh et al. Johnson
2008/0175465 A1 2008/0177183 A1		Jiang et al. Courtney et al.	2010/02/2432 A1 2010/0284590 A1		Peng et al.
2008/0180683 A1	7/2008	Kemp	2010/0290693 A1	11/2010	Cohen et al.
2008/0181477 A1	7/2008	Izatt et al.	2010/0331950 A1	12/2010	Strommer

US 9,478,940 B2

Page 8

(56)	References Cited		12/0220883 A1		Manstrom et al.	
U.S.	PATENT DOCUMENTS	20	12/0224751 A1 12/0226153 A1	9/2012	Kemp et al. Brown et al.	
2011/0010025 41	1/2011 37 1		12/0230565 A1 12/0232400 A1		Steinberg et al. Dickinson et al.	
2011/0010925 A1 2011/0015277 A1	1/2011 Nix et al. 1/2011 Thielen et al.		12/0232400 A1 12/0238869 A1	9/2012	Schmitt et al.	
2011/0021926 A1	1/2011 Spencer et al.		12/0238956 A1		Yamada et al.	
2011/0025853 A1 2011/0026797 A1	2/2011 Richardson 2/2011 Declerck et al.		12/0244043 A1 12/0250028 A1		Leblanc et al. Schmitt et al.	
2011/0020797 A1 2011/0032533 A1	2/2011 Declerck et al.	20	12/0253186 A1	10/2012	Simpson et al.	
2011/0034801 A1	2/2011 Baumgart		12/0253192 A1 12/0253276 A1		Cressman Govari et al.	
2011/0044546 A1 2011/0066073 A1	2/2011 Pan et al. 3/2011 Kuiper et al.		12/0253270 A1 12/0257210 A1		Whitney et al.	
2011/0071401 A1	3/2011 Hastings et al.		12/0262720 A1		Brown et al.	
2011/0072405 A1 2011/0077528 A1	3/2011 Chen et al. 3/2011 Kemp et al.		12/0265077 A1 12/0265268 A1		Gille et al. Blum et al.	
2011/007/328 A1 2011/0080591 A1	4/2011 Johnson et al.	20	12/0265296 A1	10/2012	McNamara et al.	
2011/0087104 A1	4/2011 Moore et al.		12/0271170 A1 12/0271175 A1		Emelianov et al. Moore et al.	
2011/0137140 A1 2011/0144502 A1	6/2011 Tearney et al. 6/2011 Zhou et al.		12/0271339 A1		O'Beirne et al.	
2011/0152771 A1	6/2011 Milner et al.		12/0274338 A1 12/0276390 A1	11/2012 11/2012	Baks et al.	
2011/0157597 A1 2011/0160586 A1	6/2011 Lu et al. 6/2011 Li et al.		12/02/0390 A1 12/0277722 A1		Gerber et al.	
2011/0178413 A1	7/2011 Schmitt et al.		12/0279764 A1		Jiang et al.	
2011/0190586 A1	8/2011 Kemp		12/0283758 A1 12/0287428 A1*		Miller et al. Tamada	G0113/10
2011/0216378 A1 2011/0220985 A1	9/2011 Poon et al. 9/2011 Son et al.	20	12/020/ 120 /11	11/2012	Tarriada	356/301
2011/0238061 A1	9/2011 van der Weide et al.		12/0289987 A1 12/0299439 A1	11/2012 11/2012	Wilson et al.	
2011/0238083 A1 2011/0245669 A1	9/2011 Moll et al. 10/2011 Zhang		12/02/99439 A1 12/03/10081 A1		Adler et al.	
2011/0249094 A1	10/2011 Wang et al.		12/0310332 A1		Murray et al.	
2011/0257545 A1 2011/0264125 A1	10/2011 Suri 10/2011 Wilson et al.		12/0319535 A1 12/0323075 A1	12/2012 12/2012	Younge et al.	
2011/0204123 A1 2011/0274329 A1	11/2011 Witson et al.	20	12/0323127 A1	12/2012	Boyden et al.	
2011/0282334 A1	11/2011 Groenhoff		12/0330141 A1 13/0015975 A1		Brown et al. Huennekens et al.	
2011/0301684 A1 2011/0306995 A1	12/2011 Fischell et al. 12/2011 Moberg		13/0023762 A1		Huennekens et al.	
2011/0319752 A1	12/2011 Steinberg		13/0023763 A1		Huennekens et al.	
2012/0004529 A1 2012/0004668 A1	1/2012 Tolkowsky et al. 1/2012 Wallace et al.		13/0026655 A1 13/0030295 A1		Lee et al. Huennekens et al.	
2012/0004008 A1 2012/0013914 A1	1/2012 Wanace et al. 1/2012 Kemp et al.		13/0030303 A1		Ahmed et al.	
2012/0016344 A1 2012/0016395 A1	1/2012 Kusakabe 1/2012 Olson		13/0030410 A1 13/0053949 A1		Drasler et al. Pintor et al.	
2012/0010393 A1 2012/0022360 A1	1/2012 Gison 1/2012 Kemp	20	13/0109958 A1	5/2013	Baumgart et al.	
2012/0026503 A1	2/2012 Lewandowski et al.		13/0109959 A1 13/0137980 A1		Baumgart et al. Waters et al.	
2012/0029007 A1 2012/0059253 A1	2/2012 Graham et al. 3/2012 Wang et al.	20	13/0150716 A1	6/2013	Stigall et al.	
2012/0059368 A1	3/2012 Takaoka et al.		13/0158594 A1 13/0218201 A1		Carrison et al. Obermiller et al.	
2012/0062843 A1 2012/0065481 A1	3/2012 Ferguson et al. 3/2012 Hunter et al.		13/0218267 A1		Braido et al.	
2012/0071823 A1	3/2012 Chen		13/0223789 A1		Lee et al.	
2012/0071838 A1 2012/0075638 A1	3/2012 Fojtik 3/2012 Rollins et al.		13/0223798 A1 13/0296704 A1		Jenner et al. Magnin et al.	
2012/0073036 A1 2012/0083696 A1	4/2012 Kitamura	20	13/0303907 A1	11/2013	Corl	
2012/0095340 A1	4/2012 Smith		13/0303920 A1 13/0310698 A1	11/2013	Corl Judell et al.	
2012/0095372 A1 2012/0108943 A1	4/2012 Sverdlik et al. 5/2012 Bates et al.				Arntsen	G02B 27/48
2012/0113108 A1	5/2012 Dala-Krishna	20	13/0331820 A1	12/2012	Itou et al.	372/3
2012/0116353 A1 2012/0130243 A1	5/2012 Arnold et al. 5/2012 Balocco et al.		13/0331820 A1 13/0338766 A1		Hastings et al.	
2012/0130247 A1	5/2012 Waters et al.		13/0339958 A1		Droste et al.	
2012/0136259 A1 2012/0136427 A1	5/2012 Milner et al. 5/2012 Palmaz et al.		14/0039294 A1 14/0180067 A1	2/2014 6/2014	Stigall et al.	
2012/0130427 A1 2012/0137075 A1	5/2012 Talliaz et al. 5/2012 Vorbach	20	14/0180128 A1	6/2014	Corl	
2012/0155734 A1	6/2012 Barratt et al.		14/0200438 A1		Millett et al.	C0112/26
2012/0158101 A1 2012/0162660 A1	6/2012 Stone et al. 6/2012 Kemp	20	14/0233030 A1*	6/2014	Tanaka	356/328
2012/0165661 A1	6/2012 Kemp et al.					
2012/0170848 A1 2012/0172698 A1	7/2012 Kemp et al. 7/2012 Teo et al.		FOREIC	IN PATE	NT DOCUMENTS	,
2012/0176607 A1	7/2012 Ott	EP	243	8877 A2	4/2012	
2012/0184853 A1 2012/0184859 A1	7/2012 Waters 7/2012 Shah et al.	GB	228	0261 A	1/1995	
2012/0184939 A1 2012/0184977 A1	7/2012 Shan et al. 7/2012 Wolf	JP JP	2000-26 2000-29		9/2000 10/2000	
2012/0215094 A1	8/2012 Rahimian et al.	JP	2001-12	5009 A	5/2001	
2012/0220836 A1 2012/0220851 A1	8/2012 Alpert et al. 8/2012 Razansky et al.	JP	2001-27		10/2001	
2012/0220831 A1 2012/0220865 A1	8/2012 Razansky et al. 8/2012 Brown et al.	JP JP	2002-37 2003-14		12/2002 5/2003	
2012/0220874 A1	8/2012 Hancock et al.	JP	2003-17		6/2003	

(56)	References Cited	Machine translation of JP 2000-097846.
	FOREIGN PATENT DOCUMENTS	Machine translation of JP 2000-321034. Machine translation of JP 2000-329534.
		Machine translation of JP 2004-004080.
JР	2003-256876 A 9/2003	Maintz et al., 1998, An Overview of Medical Image Registration
JP JP	2003-287534 A 10/2003 2005-274380 A 10/2005	Methods, Technical Report UU-CS, (22 pages).
JP	2006-184284 A 7/2006	Mamas et al., 2010, Resting Pd/Pa measured with intracoronary
JP	2006-266797 A 10/2006	pressure wire strongly predicts fractional flow reserve, Journal of
JP JP	2006-313158 A 11/2006	Invasive Cardiology 22(6):260-265.
JР JP	2007-024677 A 2/2007 2009-233001 A 10/2009	Marks et al., 1991, By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage, J. Mol. Biol. 222:581-
JР	2011-56786 A 3/2011	597.
WO	91/01156 A1 2/1991	Marks et al., 1992, By-Passing Immunization:Building High Affin-
WO WO	92/16865 A1 10/1992 93/06213 A1 4/1993	ity Human Antibodies by Chain Shuffling, BioTechnol., 10:779-
WO	93/08213 A1 4/1393 93/08829 A1 5/1993	783.
WO	98/38907 A1 9/1998	Maruno et al., 1991, Fluorine containing optical adhesives for
WO	98/57583 A1 12/1998	optical communications systems, J. Appl. Polymer. Sci. 42:2141-
WO WO	00/11511 A1 3/2000 00/44296 A1 8/2000	2148.
wo	01/11409 A2 2/2001	McCafferty et al., 1990, Phage antibodies: filamentous phage dis-
WO	03/062802 A2 7/2003	playing antibody variable domains, Nature 348:552-554. Mendieta et al., 1996, Complementary sequence correlations with
WO WO	03/073950 A1 9/2003 2004/010856 A1 2/2004	applications to reflectometry studies, Instrumentation and Develop-
WO	2004/010836 A1 2/2004 2004/023992 A1 3/2004	ment 3(6):37-46.
WO	2004/096049 A2 11/2004	Mickley, 2008, Steal Syndrome-strategies to preserve vascular
WO	2005/047813 A1 5/2005	access and extremity, Nephrol Dial Transplant 23:19-24.
WO WO	2005/106695 A2 11/2005 2006/029634 A2 3/2006	Miller et al., 2010, The MILLER banding procedure is an effective
WO	2006/037132 A1 4/2006	method for treating dialysis-associated steal syndrome, Kidney International 77:359-366.
WO	2006/039091 A2 4/2006	Milstein et al., 1983, Hybrid hybridomas and their use in
WO	2006/061829 A1 6/2006	immunohistochemistry, Nature 305:537-540.
WO WO	2006/068875 A2 6/2006 2006/111704 A1 10/2006	Mindlin et al., 1936, A force at a point of a semi-infinite solid,
WO	2006/119416 A2 11/2006	Physics, 7:195-202.
WO	2006/121851 A2 11/2006	Morrison et al., 1984, Chimeric human antibody molecules: mouse
WO WO	2006/130802 A2 12/2006 2007/002685 A2 1/2007	antigen-binding domains with human constant region domains, PNAS 81:6851-6855.
wo	2007/025230 A2 3/2007	Munson et al., 1980, Ligand: a versatile computerized approach for
WO	2007/045690 A1 4/2007	characterization of ligand-binding systems, Analytical Biochemis-
WO WO	2007/058895 A2 5/2007 2007/067323 A2 6/2007	try, 107:220-239.
wo	2007/084995 A2 7/2007	Nezam, 2008, High Speed Polygon-Scanner-Based Wavelength- Swept Laser Source in the Telescope-Less Configurations with
WO	2008/058084 A2 5/2008	Application in Optical Coherence Tomography, Optics Letters
WO WO	2008/069991 A1 6/2008 2008/107905 A2 9/2008	33(15):1741-1743.
WO	2009/009799 A1 1/2009	Nissen, 2001, Coronary Angiography and Intravascular Ultrasound,
WO	2009/009801 A1 1/2009	American Journal of Cardiology, 87(suppl):15A-20A.
WO	2009/046431 A1 4/2009	Nitenberg et al., 1995, Coronary vascular reserve in humans: a
WO WO	2009/121067 A1 10/2009 2009/137704 A1 11/2009	critical review of methods of evaluation and of interpretation of the results, Eur Heart J. 16(Suppl 1):7-21.
wo	2011/006886 A2 1/2011	Notice of Reason(s) for Refusal dated Apr. 30, 2013, for Japanese
WO	2011/038048 A1 3/2011	Patent Application No. 2011-508677 for Optical Imaging Catheter
WO WO	2011/081688 A1 7/2011 2012/003369 A2 1/2012	for Aberation Balancing to Volcano Corporation, which application
WO	2012/063369 A2 1/2012 2012/061935 A1 5/2012	is a Japanese national stage entry of PCT/US2009/043181 with
WO	2012/071388 A2 5/2012	international filing date May 7, 2009, of the same title, published on
WO	2012/087818 A1 6/2012	Nov. 12, 2009, as WO 2009/137704, and accompanying English translation of the Notice of Reason(s) for Refusal and machine
WO WO	2012/098194 A1 7/2012 2012/109676 A1 8/2012	translations of JP11-56786 and JP2004-290548 (56 pages).
wo	2012/130289 A1 10/2012	Nygren, 1982, Conjugation of horseradish peroxidase to Fab frag-
WO	2012/154767 A2 11/2012	ments with different homobifunctional and heterobifunctional
WO WO	2012/155040 A1 11/2012 2013/033414 A1 3/2013	cross-linking reagents. A comparative study, J. Histochem. and
WO	2013/033414 A1 3/2013 2013/033415 A2 3/2013	Cytochem. 30:407-412. Oesterle et al., 1986, Angioplasty at coronary bifurcations: single-
WO	2013/033418 A1 3/2013	guide, two-wire technique, Cathet Cardiovasc Diagn., 12:57-63.
WO	2013/033489 A1 3/2013	Okuno et al., 2003, Recent Advances in Optical Switches Using
WO WO	2013/033490 A1 3/2013 2013/033592 A1 3/2013	Silica-based PLC Technology, NTT Technical Review 1(7):20-30.
wo	2013/033392 A1 3/2013 2013/126390 A1 8/2013	Oldenburg et al., 1998, Nanoengineering of Optical Resonances,
WO	2014/109879 A1 7/2014	Chemical Physics Letters 288:243-247. Oldenburg et al., 2003, Fast-Fourier-Domain Delay Line for In Vivo
	OTHER PUBLICATIONS	Optical Coherence Tomography with a Polygonal Scanner, Applied Optics, 42(22):4606-4611.
		Othonos 1997 Fiber Bragg gratings Review of Scientific Instru-

Loo, 2004, Nanoshell Enabled Photonics-Based Imaging and Therapy of Cancer, Technology in Cancer Research & Treatment 3(1):33-40.

Othonos, 1997, Fiber Bragg gratings, Review of Scientific Instruments 68(12):4309-4341.

Owens et al., 2007, A Survey of General-Purpose Computation on Graphics Hardware, Computer Graphics Forum 26(1):80-113.

OTHER PUBLICATIONS

Pain et al., 1981, Preparation of protein A-peroxidase mono conjugate using a heterobifunctional reagent, and its use in enzyme immunoassays, J Immunol Methods, 40:219-30.

Park et al., 2005, Real-time fiber-based multi-functional spectral-domain optical coherence tomography at 1.3 um., Optics Express 13(11):3931-3944.

Pasquesi et al., 2006, In vivo detection of exercise induced ultrastructural changes in genetically-altered murine skeletal muscle using polarization-sensitive optical coherence tomography, Optics Express 14(4):1547-1556.

Pepe et al., 2004, Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker, American Journal of Epidemiology 159(9):882-890.

Persson et al., 1985, Acoustic impedance matching of medical ultrasound transducers, Ultrasonics, 23(2):83-89.

Placht et al., 2012, Fast time-of-flight camera based surface registration for radiotherapy patient positioning, Medical Physics 39(1):4-17.

Rabbani et al., 1999, Review: Strategies to achieve coronary arterial plaque stabilization, Cardiovascular Research 41:402-417.

Radvany et al., 2008, Plaque Excision in Management of Lower Extremity Peripheral Arterial Disease with the SilverHawk Atherectomy Catheter, Seminars in Interventional Radiology, 25(1):11-19

Reddy et al., 1996, An FFT-Based Technique for Translation, Rotation, and Scale-Invariant Image Registration, IEEE Transaction on Image Processing 5(8):1266-1271.

Riechmann et al., 1988, Reshaping human antibodies for therapy, Nature, 332:323-327.

Rivers et al., 1992, Correction of steal syndrome secondary to hemodialysis access fistulas: a simplified quantitative technique, Surgery, 112(3):593-7.

Robbin et al., 2002, Hemodialysis Arteriovenous Fistula Maturity: US Evaluation, Radiology 225:59-64.

Rollins et al., 1998, In vivo video rate optical coherence tomography, Optics Express 3:219-229.

Sarunic et al., 2005, Instantaneous Complex Conjugate Resolved Spectral Domain and Swept-Source OCT Using 3x3 Fiber Couplers, Optics Express 13(3):957-967.

Satiani et al., 2009, Predicted Shortage of Vascular Surgeons in the United States, J. Vascular Surgery 50:946-952.

Schneider et al., 2006, T-banding: A technique for flow reduction of a hyper-functioning arteriovenous fistula, J Vase Surg. 43(2):402-405

Sen et al., 2012, Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis, Journal of the American College of Cardiology 59(15):1392-1402.

Setta et al., 2005, Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis, analysis, Human Reproduction, 20(11):3114-3121.

Seward et al., 1996, Ultrasound Cardioscopy: Embarking on New Journey, Mayo Clinic Proceedings 71(7):629-635.

Shen et al., 2006, Eigengene-based linear discriminant model for tumor classification using gene expression microarray data, Bioinformatics 22(21):2635-2642.

Abdi et al., 2010, Principal component analysis, Wiley Interdisciplinary Reviews: Computational Statistics 2:433-459.

Adler et al., 2007, Phase-Sensitive Optical Coherence Tomography at up to 370,000 Lines Per Second Using Buffered Fourier Domain Mode-Locked Lasers, Optics Letters, 32(6):626-628.

Agresti, 1996, Models for Matched Pairs, Chapter 8, An Introduction to Categorical Data Analysis, Wiley-Interscience A John Wiley & Sons, Inc., Publication, Hoboken, New Jersey.

Akasheh et al., 2004, Development of piezoelectric micromachined ultrasonic transducers, Sensors and Actuators A Physical, 111:275-287

Amini et al., 1990, Using dynamic programming for solving variational problems in vision, IEEE Transactions on Pattern Analysis and Machine Intelligence, 12(9):855-867.

Bail et al., 1996, Optical coherence tomography with the "Spectral Radar"—Fast optical analysis in volume scatterers by short coherence interferometry, Optics Letters 21(14):1087-1089.

Bain, 2011, Privacy protection and face recognition, Chapter 3, Handbook of Face Recognition, Stan et al., Springer-Verlag.

Barnea et al., 1972, A class of algorithms for fast digital image registration, IEEE Trans. Computers, 21(2):179-186.

Blanchet et al., 1993, Laser Ablation and the Production of Polymer Films, Science, 262(5134):719-721.

Bonnema, 2008, Imaging Tissue Engineered Blood Vessel Mimics with Optical Tomography, College of Optical Sciences dissertation, University of Arizona (252 pages).

Bouma et al., 1999, Power-efficient nonreciprocal interferometer and linear-scanning fiber-optic catheter for optical coherence tomography, Optics Letters, 24(8):531-533.

Breiman, 2001, Random forests, Machine Learning 45:5-32.

Brown, 1992, A survey of image registration techniques, ACM Computing Surveys 24(4):325-376.

Bruining et al., 2009, Intravascular Ultrasound Registration/Integration with Coronary Angiography, Cardiology Clinics, 27(3):531-540

Brummer, 1997, An euclidean distance measure between covariance matrices of speechcepstra for text-independent speaker recognition, in Proc. South African Symp. Communications and Signal Processing:167-172.

Burr et al., 2005, Searching for the Center of an Ellipse in Proceedings of the 17th Canadian Conference on Computational Geometry:260-263.

Canny, 1986, A computational approach to edge detection, IEEE Trans. Pattern Anal. Mach. Intell. 8:679-698.

Cavalli et al., 2010, Nanosponge formulations as oxygen delivery systems, International Journal of Pharmaceutics 402:254-257.

Choma et al., 2003, Sensitivity Advantage of Swept Source and Fourier Domain Optical Coherence Tomography, Optics Express 11(18):2183-2189.

Clarke et al., 1995, Hypoxia and myocardial ischaemia during peripheral angioplasty, Clinical Radiology, 50(5):301-303.

Collins, 1993, Coronary flow reserve, British Heart Journal 69:279-281.

Communication Mechanisms for Distributed Real-Time Applications, NI Developer Zone, http://zone.ni.eom/devzone/cda/tut/p/id/3105, accessed Jul. 23, 2007.

Cook, 2007, Use and misuse of receiver operating characteristic curve in risk prediction, Circulation 115(7):928-35.

D'Agostino et al., 2001, Validation of the Framingham coronary heart disease prediction score: results of a multiple ethnic group investigation, JAMA 286:180-187.

David et al., 1974, Protein iodination with solid-state lactoperoxidase, Biochemistry 13:1014-1021.

Davies et al., 1985, Plaque fissuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina, British Heart Journal 53:363-373.

Davies et al., 1993, Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content, British Heart Journal 69:377-381.

Deterministic Data Streaming in Distributed Data Acquisition Systems, NI Developer Zone, "What is Developer Zone?", http://zone.ni.eom/devzone/cda/tut/p/id/3105, accessed Jul. 23, 2007.

Eigenwillig, 2008, K-Space Linear Fourier Domain Mode Locked Laser and Applications for Optical Coherence Tomography, Optics Express 16(12):8916-8937.

Elghanian et al., 1997, Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles, Science, 277(5329):1078-1080.

Ergun et al., 2003, Capacitive Micromachined Ultrasonic Transducers: Theory and Technology, Journal of Aerospace Engineering, 16(2):76-84.

Evans et al., 2006, Optical coherence tomography to identify intramucosa carcinoma and high-grade dysplasia in Barrett's esophagus, Clin Gast Hepat 4(1):38-43.

OTHER PUBLICATIONS

Fatemi et al., 1999, Vibro-acoustography: an imaging modality based on ultrasound-stimulated acoustic emission, PNAS U.S.A., 96(12):6603-6608.

Felzenszwalb et al., 2005, Pictorial Structures for Object Recognition, International Journal of Computer Vision, 61(1):55-79.

Ferring et al., 2008, Vasculature ultrasound for the pre-operative evaluation prior to arteriovenous fistula formation for haemodialysis: review of the evidence, Nephrol. Dial. Transplant. 23(6):1809-1815.

Fischler et al., 1973, The representation and matching of pictorial structures, IEEE Transactions on Computer 22:67-92.

Fleming et al., 2010, Real-time monitoring of cardiac radio-frequency ablation lesion formation using an optical coherence tomography forward-imaging catheter, Journal of Biomedical Optics 15 (3):030516-1 (3 pages).

Fookes et al., 2002, Rigid and non-rigid image registration and its association with mutual information: A review, Technical Report ISBN:1 86435 569 7, RCCVA, QUT.

Forstner & Moonen, 1999, A metric for covariance matrices, In Technical Report of the Dpt of Geodesy and Geoinformatics, Stuttgart University, 113-128.

Goel et al., 2006, Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) for treatment of dialysis access-associated steal syndrome, Kidney Int 70(4):765-70.

Gotzinger et al., 2005, High speed spectral domain polarization sensitive optical coherence tomography of the human retina, Optics Express 13(25):10217-10229.

Gould et al., 1974, Physiologic basis for assessing critical coronary stenosis, American Journal of Cardiology, 33:87-94.

Griffiths et al., 1993, Human anti-self antibodies with high specificity from phage display libraries, The EMBO Journal, 12:725-734. Griffiths et al., 1994, Isolation of high affinity human antibodies directly from large synthetic repertoires, The EMBO Journal, 13(14):3245-3260.

Grund et al., 2010, Analysis of biomarker data:logs, odds, ratios and ROC curves, Curr Opin HIV AIDS 5(6):473-479.

Harrison et al., 2011, Guidewire Stiffness: What's in a name?, J Endovasc Ther, 18(6):797-801.

Huber et al., 2005, Amplified, Frequency Swept Lasers for Frequency Domain Reflectometry and OCT Imaging: Design and Scaling Principles, Optics Express 13(9):3513-3528.

Huber et al., 2006, Fourier Domain Mode Locking (FDML): A New Laser Operating Regime and Applications for Optical Coherence Tomography, Optics Express 14(8):3225-3237.

International Search Report and Written Opinion mailed Mar. 11, 2014, for International Patent Application No. PCT/US13/75675, filed Dec. 17, 2013 (7 pages).

International Search Report and Written Opinion mailed Mar. 19, 2014, for International Patent Application No. PCT/US13/075353, filed Dec. 16, 2013 (8 pages).

Sihan et al., 2008, A novel approach to quantitative analysis of intraluminal optical coherence tomography imaging, Comput. Cardiol:1089-1092.

Siwy et al., 2003, Electro-responsive asymmetric nanopores in polyimide with stable ion-current signal, Applied Physics A: Materials Science & Processing 76:781-785.

Smith et al., 1989, Absolute displacement measurements using modulation of the spectrum of white light in a Michelsor interferometer, Applied Optics, 28(16):3339-3342.

Smith, 1997, The Scientist and Engineer's Guide to Digital Signal Processing, California Technical Publishing, San Diego, CA:432-436.

Soller, 2003, Polarization diverse optical frequency domain interferometry: All coupler implementation, Bragg Grating, Photosensitivity, and Poling in Glass Waveguides Conference MB4:30-32

Song et al., 2012, Active tremor cancellation by a "Smart" handheld vitreoretinal microsurgical tool using swept source optical coherence tomography, Optics Express, 20(21):23414-23421.

Stenqvist et al., 1983, Stiffness of central venous catheters, Acta Anaesthesiol Scand., 2:153-157.

Strickland, 1970, Time-Domain Reflectometer Measurements, Tektronix, Beaverton, OR, (107 pages).

Strobl et al., 2009, An Introduction to Recursive Partitioning:Rationale, Application and Characteristics of Classification and Regression Trees, Bagging and Random Forests, Psychol Methods., 14(4):323-348.

Sutcliffe et al., 1986, Dynamics of UV laser ablation of organic polymer surfaces, Journal of Applied Physics, 60(9):3315-3322.

Suzuki, 2013, A novel guidewire approach for handling acute-angle bifurcations, J Inv Cardiol 25(1):48-54.

Tanimoto et al., 2008, A novel approach for quantitative analysis of intracoronary optical coherence tomography: high inter-observer agreement with computer-assisted contour detection, Cathet Cardiovascular Intervent., 72(2):228-235.

Tearney et al., 1997, In vivo Endoscopic Optical Biopsy with Optical Coherence Tomography, Science, 276:2037-2039.

Tonino et al., 2009, Fractional flow reserve versus angiography for guiding percutaneous coronary intervention, The New England Journal of Medicine, 360:213-224.

Toregeani et al., 2008, Evaluation of hemodialysis arteriovenous fistula maturation by color-flow Doppler ultrasound, J Vasc. Bras. 7(3):203-213.

Translation of Notice of Reason(s) for Refusal dated Apr. 30, 2014, for Japanese Patent Application No. 2011-508677, (5 pages).

Translation of Notice of Reason(s) for Refusal dated May 25, 2012, for Japanese Patent Application No. 2009-536425, (3 pages).

Translation of Notice of Reason(s) for Refusal dated Nov. 22, 2012, for Japanese Patent Application No. 2010-516304, (6 pages).

Traunecker et al., 1991, Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells EMBO J., 10:3655-3659.

Trolier-McKinstry et. al., 2004, Thin Film Piezoelectric for MEMS, Journal of Electroceramics 12:7-17.

Tuniz et al., 2010, Weaving the invisible thread: design of an optically invisible metamaterial fibre, Optics Express 18(17):18095-18105

Turk et al., 1991, Eigenfaces for Recognition, Journal of Cognitive Neuroscience 3(1):71-86.

Tuzel et al., 2006, Region Covariance: A Fast Descriptor for Detection and Classification, European Conference on Computer Vision (ECCV).

Urban et al., 2010, Design of a Pressure Sensor Based on Optical Bragg Grating Lateral Deformation, Sensors (Basel), 10(12):11212-11225.

Vakhtin et al., 2003, Common-path interferometer for frequency-domain optical coherence tomography, Applied Optics, 42(34):6953-6958.

Vakoc et al., 2005, Phase-Resolved Optical Frequency Domain Imaging, Optics Express 13(14):5483-5493.

Verhoeyen et al., 1988, Reshaping human antibodies: grafting an antilysozyme activity, Science, 239:1534-1536.

Villard et al., 2002, Use of a blood substitute to determine instantaneous murine right ventricular thickening with optical coherence tomography, Circulation, 105:1843-1849.

Wang et al., 2002, Optimizing the Beam Patten of a Forward-Viewing Ring-Annular Ultrasound Array for Intravascular Imaging, Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 49(12).

Wang et al., 2006, Multiple biomarkers for the prediction of first major cardiovascular events and death, The New England Journal of Medicine, 355(25):2631-2639.

Wang et al., 2009, Robust Guidewire Tracking in Fluoroscopy, IEEE Conference on Computer Vision and Pattern Recognition—CVPR 2009:691-698.

Wang et al., 2011, In vivo intracardiac optical coherence tomography imaging through percutaneous access: toward image-guided radio-frequency ablation, J. Biomed. Opt. 0001 16(11):110505-1 (3 pages).

Waterhouse et. al., 1993, Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires, Nucleic Acids Res., 21:2265-2266.

OTHER PUBLICATIONS

Wegener, 2011, 3D Photonic Metamaterials and Invisibility Cloaks: The Method of Making, MEMS 2011, Cancun, Mexico, Jan. 23-27, 2011

West et al., 1991, Arterial insufficiency in hemodialysis access procedures: correction by banding technique, Transpl Proc 23(2):1838-40.

Wyawahare et al., 2009, Image registration techniques: an overview, International Journal of Signal Processing, Image Processing and Pattern Recognition, 2(3):11-28.

Yaqoob et al., 2006, Methods and application areas of endoscopic optical coherence tomography, J. Biomed. Opt., 11, 063001-1-063001-19.

Yasuno et al., 2004, Polarization-sensitive complex Fourier domain optical coherence tomography for Jones matrix imaging of biological samples, Applied Physics Letters 85(15):3023-3025.

Zhang et al., 2004, Full range polarization-sensitive Fourier domain optical coherence tomography, Optics Express, 12(24):6033-6039. Zitova et al., 2003, Image registration methods: A survey. Image and Vision Computing, 21(11):977-1000.

International Search Report and Written Opinion mailed Nov. 2, 2012, for International Patent Application No. PCT/US12/53168, filed Aug. 30, 2013 (8 pages).

International Search Report and Written Opinion mailed on Apr. 14, 2014, for International Patent Application No. PCT/US2013/076148, filed Dec. 18, 2013 (8 pages).

International Search Report and Written Opinion mailed on Apr. 21, 2014, for International Patent Application No. PCT/US2013/076015, filed Dec. 18, 2013 (7 pages).

International Search Report and Written Opinion mailed on Apr. 23, 2014, for International Patent Application No. PCT/US2013/075328, filed Dec. 16, 2013 (8 pages).

International Search Report and Written Opinion mailed on Apr. 29, 2014, for International Patent Application No. PCT/US13/76093, filed Dec. 18, 2013 (6 pages).

International Search Report and Written Opinion mailed on Apr. 9, 2014, for International Patent Application No. PCT/US13/75089, filed Dec. 13, 2013 (7 pages).

International Search Report and Written Opinion mailed on Feb. 21, 2014, for International Patent Application No. PCT/US13/76053, filed Dec. 18, 2013 (9 pages).

International Search Report and Written Opinion mailed on Feb. 21, 2014, for International Patent Application No. PCT/US2013/076965, filed Dec. 20, 2013 (6 pages).

International Search Report and Written Opinion mailed on Feb. 27, 2014, for International Patent Application No. PCT/US13/75416, filed Dec. 16, 2013 (7 pages).

International Search Report and Written Opinion mailed on Feb. 28, 2014, for International Patent Application No. PCT/US13/75653, filed Dec. 17, 2013 (7 pages).

International Search Report and Written Opinion mailed on Feb. 28, 2014, for International Patent Application No. PCT/US13/75990, filed Dec. 18, 2013 (7 pages).

International Search Report and Written Opinion mailed on Jan. 16, 2009, for International Patent Application No. PCT/US08/78963 filed on Oct. 6, 2008 (7 Pages).

International Search Report and Written Opinion mailed on Jul. 30, 2014, for International Patent Application No. PCT/US14/21659, filed Mar. 7, 2014 (15 pages).

International Search Report and Written Opinion mailed on Mar. 10, 2014, for International Patent Application No. PCT/US2013/076212, filed Dec. 18, 2013 (8 pages).

International Search Report and Written Opinion mailed on Mar. 11, 2014, for International Patent Application No. PCT/US13/76173, filed Dec. 16, 2013 (9 pages).

International Search Report and Written Opinion mailed on Mar. 11, 2014, for International Patent Application No. PCT/US13/76449, filed Dec. 19, 2013 (9 pages).

International Search Report and Written Opinion mailed on Mar. 18, 2014, for International Patent Application No. PCT/US2013/076502, filed Dec. 19, 2013 (7 pages).

International Search Report and Written Opinion mailed on Mar. 18, 2014, for International Patent Application No. PCT/US2013/076788, filed Dec. 20, 2013 (7 pages).

International Search Report and Written Opinion mailed on Mar. 19, 2014, for International Patent Application No. PCT/US13/75349, filed Dec. 16, 2013 (10 pages).

International Search Report and Written Opinion mailed on Mar. 19, 2014, for International Patent Application No. PCT/US2013/076587, filed Dec. 19, 2013 (10 pages).

International Search Report and Written Opinion mailed on Mar. 19, 2014, for International Patent Application No. PCT/US2013/076909, filed Dec. 20, 2013 (7 pages).

International Search Report and Written Opinion mailed on Mar. 7, 2014, for International Patent Application No. PCT/US2013/076304, filed Dec. 18, 2013 (9 pages).

International Search Report and Written Opinion mailed on Mar. 7, 2014, for International Patent Application No. PCT/US2013/076480, filed Dec. 19, 2013 (8 pages).

International Search Report and Written Opinion mailed on Mar. 7, 2014, for International Patent Application No. PCT/US2013/076512, filed Dec. 19, 2013 (8 pages).

International Search Report and Written Opinion mailed on Mar. 7, 2014, for International Patent Application No. PCT/US2013/076531, filed Dec. 19, 2013 (10 pages).

Jakobovits et al., 1993, Analysis of homozygous mutant chimeric mice:deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production, PNAS USA 90:2551-255.

Jakobovits et al., 1993, Germ-line transmission and expression of a human-derived yeast artificial chromosome, Nature 362:255-258.

Jang et al., 2002, Visualization of Coronary Atherosclerotic Plaques in Patients Using Optical Coherence Tomography: Comparison With Intravascular Ultrasound, Journal of the American College of Cardiology 39:604-609.

Jiang et al., 1992, Image registration of multimodality 3-D medical images by chamfer matching, Proc. SPIE 1660, Biomedical Image Processing and Three-Dimensional Microscopy, 356-366.

Johnson et al., 1993, Human antibody engineering: Current Opinion in Structural Biology, 3:564-571.

Jones et al., 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321:522-525.

Juviler et al., 2008, Anorectal sepsis and fistula-in-ano, Surgical Technology International, 17:139-149.

Karapatis et al., 1998, Direct rapid tooling:a review of current research, Rapid Prototyping Journal, 4(2):77-89.

Karp et al., 2009, The benefit of time-of-flight in PET imaging, J Nucl Med 49:462-470.

Kelly et al., 2005, Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle, Circulation Research 96:327-336.

Kemp et al., 2005, Depth Resolved Optic Axis Orientation in Multiple Layered Anisotropic Tissues Measured with Enhanced Polarization Sensitive Optical Coherence Tomography, Optics Express 13(12):4507-4518.

Kersey et al., 1991, Polarization insensitive fiber optic Michelson interferometer, Electron. Lett. 27:518-520.

Kheir et al., 2012, Oxygen Gas-Filled Microparticles Provide Intravenous Oxygen Delivery, Science Translational Medicine 4(140):140ra88 (10 pages).

Khuri-Yakub et al., 2011, Capacitive micromachined ultrasonic transducers for medical imaging and therapy, J Micromech Microeng. 21(5):054004-054014.

Kirkman, 1991, Technique for flow reduction in dialysis access fistulas, Surg Gyn Obstet, 172(3):231-3.

OTHER PUBLICATIONS

Kohler et al., 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-7.

Koo et al., 2011, Diagnosis of IschemiaCausing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms, J Am Coll Cardiol 58(19):1989-1997.

Kozbor et al., 1984, A human hybrid myeloma for production of human monoclonal antibodies, J. Immunol., 133;3001-3005.

Kruth et al., 2003, Lasers and materials in selective laser sintering, Assembly Automation, 23(4):357-371.

Kumagai et al., 1994, Ablation of polymer films by a femtosecond high-peak-power Ti:sapphire laser at 798 nm, Applied Physics Letters, 65(14):1850-1852.

Larin et al., 2002, Noninvasive Blood Glucose Monitoring with Optical Coherence Tomography: a pilot study in human subjects, Diabetes Care, 25(12):2263-7.

Larin et al., 2004, Measurement of Refractive Index Variation of Physiological Analytes using Differential Phase OCT, Proc of SPIE 5325:31-34.

Laufer, 1996, Introduction to Optics and Lasers in Engineering, Cambridge University Press, Cambridge UK:156-162.

Lefevre et al., 2001, Stenting of bifurcation lesions:a rational approach, J. Interv. Cardiol., 14(6):573-585.

Li et al., 2000, Optical Coherence Tomography: Advanced Technology for the Endoscopic Imaging of Barrett's Esophagus, Endoscopy, 32(12):921-930.

International Search Report and Written Opinion mailed Mar. 19, 2014, for International Application No. PCT/US13/63483, filed Oct. 4, 2013 (6 pages).

* cited by examiner




FIG.1




FIG.2




FIG.3

Thorlabs BOA1130S and BOA1130P

		BOA1130S and BOA1130P			
Item#		Min	Typical	Min	
Operating Current	I _{OP}	-	700 mA	750 mA	
Center Wavelength	λ _C	1265 nm	1285 nm	1295 nm	
Optical 3 dB Bandwidth	BW	80 nm	87 nm	-	
Saturation Output Power (@ -3 dB)	P _{SAT}	15 dBm	17 dBm	-	
Small Signal Gain (@ Pin = -20 dBm, λ = 1312 nm)	G	27 dB	30 dB	-	
Gain Ripple (RMS) @ I _{OP}	ōG	-	0.2 dB	0.3 dB	
Noise Figure	NF	-	7.0	9.0	
Forward Voltage	V_{F}	1	1.6 V	2.0 V	
Chip Length	ı	1	1.5 mm	-	
Waveguide Refractive Index	-	-	3.2	-	
TEC Operation (Typ./Max @ T _{CASE} = 25/70 °C)					
- TEC Current	I _{TEC}	-	0.4 A	1.5 A	
- TEC Voltage	V _{TEC}	-	0.5 V	4.0 V	
- Thermistor Resistance	R _{TH}	-	10 ΚΩ	-	

FIG.4




FIG.5




FIG.6




FIG.7




FIG.8




FIG.9




FIG.10




FIG.11







FIG.12







SYSTEMS AND METHODS FOR AMPLIFYING LIGHT

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of, and priority to, U.S. Provisional Patent Application No. 61/710,424, filed Oct. 5, 2012, the contents of which are incorporated by reference.

FIELD OF THE INVENTION

The invention generally relates to systems and methods for amplifying light.

BACKGROUND

Optical systems are used in a variety of applications that require amplified light at a particular wavelength, such as optical communication networks, medical imaging, and atmospheric remote sensing. Amplified light is provided by a light source that includes an optical amplifier. An optical amplifier amplifies light by passing it through a gain medium. The gain medium is a material that increases the power of light by stimulated emission when supplied with energy. Where laser light is desired, the gain medium is positioned between a pair of mirrors known as an optical cavity. Input light resonates between the mirrors while being re-amplified by the gain medium until the lasing threshold is surpassed and laser light is produced.

A gain medium has a peak gain associated with a transition frequency of its constituent elements. Light having a wavelength at the peak gain is more readily and more robustly amplified than light at other wavelengths. Consequently, the lasing threshold is lowest at the peak gain.

Where an optical system requires a particular wavelength of amplified light, the light source may include a tunable 35 optical filter. Amplified light of a selected wavelength is obtained by tuning the filter to that wavelength and sending the light into the gain medium with sufficient input power to achieve a desired output power. However, while providing light of a selected wavelength, tunable optical filters also 40 emit a low background level of light across a broad spectrum of wavelengths. When the input power is high enough to successfully amplify a selected frequency not at peak gain, the input power of background light at the peak gain can surpass the lasing threshold, resulting in undesired lasing, 45 i.e., parasitic lasing. This so-called parasitic lasing leaches energy from the system, creates spurious spectral peaks, adds noise to optical signals, and diminishes the power of amplified light at the selected wavelength.

As a consequence, the useful range of a tunable filter is 50 limited. For existing light sources to be used effectively, the tunable optical filter must be kept within a narrow tuning range surrounding the peak gain of the optical amplifier. Thus, once a light source is deployed in an optical system, use of the entire system is restricted by the gain medium of 55 the optical amplifier to a narrow range of wavelengths defined by a peak gain of the gain medium. A variety of optical applications in medicine, research, and communication require a range of wavelengths of light broader than existing optical systems can handle and performing these applications requires multiple optical systems, each built around its own gain medium.

SUMMARY

The invention provides optical amplifier devices, systems, and methods that suppress parasitic lasing. Devices and

2

methods of the invention suppress parasitic lasing by employing wavelength-dependent reflectivity that inhibits reflection at a peak gain of a gain medium without inhibiting reflection at wavelengths not at the peak gain. Devices and methods of the invention inhibit reflection of light near the peak gain and even when a tunable filter is used, as low level background light from the filter does not exceed the lasing threshold of the gain medium. This allows the optical amplifier to amplify light across a broad range of wavelengths without parasitic lasing, thereby increasing the useable range of a tunable optical filter. In this manner, light at wavelengths not at a peak gain can be used effectively, and the gain medium of an optical amplifier does not limit use of a system to a narrow range of wavelengths associated with 15 a peak gain of the gain medium. Thus, a single optical system according to the invention can be used for applications that require a broad range of wavelengths.

In certain aspects, the invention provides a method for amplifying light that includes transmitting light through a gain medium in which the light includes wavelengths at the peak gain of the gain medium and wavelengths not at the peak gain. Substantially all reflection of the light at the peak gain wavelengths is inhibited, thereby allowing amplification of the light not at the peak gain. The application provides techniques to selectively inhibit reflection at the peak gain wavelengths and not inhibit reflection at wavelengths not at the peak gain, preferably not inhibiting reflection at wavelengths both above and below the peak gain. In certain embodiments, the invention utilizes surface coatings that inhibit reflection in a wavelength-dependent matter, for example, inhibiting substantially all reflection at a peak gain. In certain embodiments, a gain medium is included that is solid with at least one surface facet that transmits or reflects light. Materials for use with systems and methods of the invention can be used to coat a facet of a gain medium or a surface in an optical path such as a mirror. A coated mirror can be any mirror within the optical path of a light source, such as one of the mirrors in a tunable etalon or either reflector in an optical cavity. In some embodiments, systems and methods of the invention use a wavelengthdependent mirror as an output coupler for a laser or optical amplifier.

By inhibiting substantially all reflection at the peak gain of a gain medium, the input power of an optical amplifier can be increased. Systems and methods of the invention diminish the power of those wavelengths of light corresponding to a lowest lasing threshold of the gain medium, allowing light of a selected wavelength to be usably amplified without parasitic lasing. By suppressing parasitic lasing in the gain medium, devices and methods of the invention allow a tunable optical filter to be tuned across a range of wavelengths greater than previously possible for a given gain medium. Methods of the invention can be used with any gain medium known in the art including, for example and without limitation, a semiconductor gain medium as found, for example, in a semiconductor optical amplifier or a booster optical amplifier.

In certain aspects, the invention provides a semiconductor optical amplifier including a semiconductor gain medium and a material that inhibits substantially all reflection at the peak gain, thus allowing the gain medium to amplify light at wavelengths not at the peak gain without parasitic lasing. The material can be provided as a mirror or as one of the facets of a solid gain medium. For example, an end facet of a semiconductor optical amplifier or booster optical amplifier or a mirror of an optical cavity can be coated with the material.

In other aspects, the invention provides a system for producing coherent light, including an optical amplifier with a reflector in optical communication with the optical amplifier in which the reflector inhibits reflection of light at the peak gain and reflects light at wavelengths not at the peak gain, thereby suppressing parasitic lasing. The optical amplifier produces coherent near infrared light from incident light delivered by a filter module in optical connection to the optical amplifier. Preferably, the reflector is an output coupler and the optical amplifier is a semiconductor optical amplifier. In certain embodiments, the system includes an output mechanism configured to be coupled to a fiber optic interferometer or other imaging device.

Systems and methods of the invention may be employed in any industry or application including, for example, medical imaging. In certain embodiments, the invention provides systems and methods for providing light for imaging tissue. For example, systems of the invention can generate coherent, near-infrared light without parasitic lasing for use in optical coherence tomography (OCT).

BRIEF DESCRIPTION OF THE DRAWINGS

- FIG. 1 illustrates photon emission.
- FIG. 2 is a schematic diagram of a semiconductor optical 25 amplifier.
- $\hat{\mathrm{FIG}}$. 3 shows the emission wavelengths of semiconductor materials.
- FIG. 4 is a specification sheet for a booster optical amplifier.
 - FIG. 5 is a gain curve for a booster optical amplifier.
 - FIG. 6 shows an optical component.
 - FIG. 7 is a diagram of a laser.
 - FIG. 8 shows a gain curve showing a peak gain.
- FIG. 9 shows wavelength dependent reflectivity of a 35 material of the invention.
 - FIG. 10 is a diagram of a light path within an optical filter.
- FIG. 11 is a diagram of an optical system according to certain embodiments of the invention.
- FIG. 12 is a high-level diagram of a system for optical 40 coherence tomography.
- FIG. 13 is a schematic diagram of the imaging engine of an OCT system.
 - FIG. 14 is a diagram of a light path in an OCT system.
- FIG. 15 shows the organization of a patient interface 45 module in an OCT system.

DETAILED DESCRIPTION

The invention generally provides systems and methods 50 for amplifying light using a gain component that includes a gain medium, in which the light includes wavelengths at a peak gain of the gain medium and wavelengths not at the peak gain. Any device that amplifies light that is compatible with systems and methods of the invention may be used as 55 the gain component, such as, for example and without limitation, a semiconductor optical amplifier, a laser, or a booster optical amplifier. Systems and methods of the invention also include one or more components within an optical path that selectively inhibit reflection in a wavelength 60 dependent fashion. Reflection can be inhibited by any method known in the art such as a coating on a surface. In certain embodiments, a mirror is provided having a surface coated to reflect light in a wavelength dependent manner.

Systems of the invention include gain components, components for wavelength dependent reflection, and any other compatible component known in the art including optical 4

filters, fibers, coupling mechanisms, and interferometers. In certain embodiments, an optical filter is a tunable optical filter. Systems of the invention may further include other application-specific hardware, firmware, and software. For example, in certain embodiments, the invention generally relates to a system to operate as a light source for optical coherence tomography (OCT) for use in imaging a lumen biological tissue.

Systems of the invention generally include at least one gain component that amplifies the power of light that is transmitted through it. When light interacts with material, a few outcomes may be obtained. Light can be transmitted through the material unaffected or reflect off of a surface of the material. Alternatively, an incident photon of light can exchange energy with an electron of an atom within the material by either absorption or stimulated emission. As shown in FIG. 1, if the photon is absorbed, the electron 101 transitions from an initial energy level E1 to a higher energy level E2 (in three-level systems, there is a transient energy state associated with a third energy level E3).

When electron 101 returns to ground state E1, a photon 105 is emitted. When photons are emitted, there is net increase in power of light within the gain medium. In stimulated emission, an electron emits energy ΔE through the creation of a photon of frequency v_{12} and coherent with the incident photon. Two photons are coherent if they have the same phase, frequency, polarization, and direction of travel. Equation 1 gives the relationship between energy change ΔE and frequency v_{12} :

$$\Delta E = h v_{12} \tag{1}$$

where h is Plank's constant. Light produced this way can be temporally coherent, i.e., having a single location that exhibits clean sinusoidal oscillations over time.

An electron can also release a photon by spontaneous emission. Amplified spontaneous emission (ASE) in a gain medium produces spatially coherent light, e.g., having a fixed phase relationship across the profile of a light beam.

Emission prevails over absorption when light is transmitted through a material having more excited electrons than ground state electrons—a state known as a population inversion. A population inversion can be obtained by pumping in energy (e.g., current or light) from outside. Where emission prevails, the material exhibits a gain G defined by Equation 2:

$$G=10 \operatorname{Log}_{10}(P_{out}/P_{in}) dB$$
 (2)

where P_{out} and P_{in} are the optical output and input power of the gain medium.

Systems of the invention include one or more gain components for use as a light source. A gain component, generally, refers to any device known in the art capable of amplifying light such as an optical amplifier, laser, or any component employing a gain medium. A gain medium is a material that increases the power of light that is transmitted through the gain medium. Exemplary gain mediums include crystals (e.g., sapphire), doped crystals (e.g., yttrium aluminum garnet, yttrium orthovanadate), glasses such as silicate or phosphate glasses, gasses (e.g., mixtures of helium and neon, nitrogen, argon, or carbon monoxide), semiconductors (e.g., gallium arsenide, indium gallium arsenide), and liquids (e.g., rhodamine, fluorescein).

A gain component can be an optical amplifier or a laser. An optical amplifier is a device that amplifies an optical signal directly, without the need to first convert it to an electrical signal. An optical amplifier generally includes a gain medium (e.g., without an optical cavity), or one in

which feedback from the cavity is suppressed. Exemplary optical amplifiers include doped fibers, bulk lasers, semiconductor optical amplifiers (SOAs), and Raman optical amplifiers. In doped fiber amplifiers and bulk lasers, stimulated emission in the amplifier's gain medium causes ampli- 5 fication of incoming light. In semiconductor optical amplifiers (SOAs), electron-hole recombination occurs. In Raman amplifiers, Raman scattering of incoming light with phonons (i.e., excited state quasiparticles) in the lattice of the gain medium produces photons coherent with the incoming pho- 10

Doped fiber amplifiers (DFAs) are optical amplifiers that use a doped optical fiber as a gain medium to amplify an optical signal. In a DFA, the signal to be amplified and a pump laser are multiplexed into the doped fiber, and the 15 signal is amplified through interaction with the doping ions. The most common example is the Erbium Doped Fiber Amplifier (EDFA), including a silica fiber having a core doped with trivalent Erbium ions. An EDFA can be efficiently pumped with a laser, for example, at a wavelength of 20 980 nm or 1.480 nm, and exhibits gain, e.g., in the 1.550 nm region. An exemplary EDFA is the Cisco ONS 15501 EDFA from Cisco Systems, Inc. (San Jose, Calif.).

Semiconductor optical amplifiers (SOAs) are amplifiers that use a semiconductor to provide the gain medium. FIG. 25 2 is a schematic diagram of a semiconductor optical amplifier. Input light 213 is transmitted through gain medium 201 and amplified output light 205 is produced. An SOA includes n-cladding layer 217 and p-cladding layer 209. An SOA typically includes a group III-V compound semiconductor 30 such as GaAs/AlGaAs, InP/InGaAs, InP/InGaAsP and InP/ InAlGaAs, though any suitable semiconductor material may be used. FIG. 3 shows the emission wavelengths of semiconductor materials.

A typical semiconductor optical amplifier includes a 35 double heterostructure material with n-type and p-type high band gap semiconductors around a low band gap semiconductor. The high band gap layers are sometimes referred to as p-cladding and n-cladding layers (having, by definition, more holes than electrons and more electrons than holes, 40 optical amplifier or a laser amplifies light in a frequencyrespectively). The carriers are injected into the gain medium where they recombine to produce photons by both spontaneous and stimulated emission. The cladding layers also function as waveguides to guide the propagation of the light signal. Semiconductor optical amplifiers are described in 45 equation 3: Dutta and Wang, Semiconductor Optical Amplifiers, 297 pages, World Scientific Publishing Co. Pte. Ltd., Hackensack, N.J. (2006), the contents of which are hereby incorporated by reference in their entirety.

Booster Optical Amplifiers (BOAs) are single-pass, trav- 50 eling-wave amplifiers that only amplify one state of polarization generally used for applications where the input polarization of the light is known. Since a BOA is polarization sensitive, it can provide desirable gain, noise, bandwidth, and saturation power specifications. In some embodi- 55 ments, a BOA includes a semiconductor gain medium (i.e., is a class of SOA). In certain embodiments, a BOA includes an InP/InGaAsP Multiple Quantum Well (MQW) layer structure. The input and output of BOA can be coupled to one or more waveguides on an optical amplifier chip. FIG. 60 4 is a specification sheet and FIG. 5 is a gain curve for a COTS booster optical amplifier.

As shown in FIG. 6, optical amplifier components can be provided in a standard 14-pin butterfly package with either single mode fiber (SMF) or polarization maintain fiber 65 (PMF) pigtails, which can be terminated with any fixed connection (FC) connector such as an angled physical

6

connection (FC/APC) connector. Optional polarizationmaintaining isolators can be provided at the input, output or both. In certain embodiments, the invention provides a wavelength dependent reflector as a reflective surface with an optical amplifier, such as a mirror or one of the facets of the gain medium.

A laser generally is an optical amplifier in which the gain medium is positioned within an optical resonator (i.e., an optical cavity) as diagramed in FIG. 7. An optical resonator is an arrangement of mirrors that forms a standing wave cavity resonator for light waves, e.g., a pair of mirrors on opposite ends of the gain medium and facing each other. The pair includes high reflector 717 and output coupler 705 surrounding gain medium 701. Incident light 721 reflects between the mirrors creating standing wave 713. Some light is emitted as laser beam 709. Where laser light is desired, the gain medium is positioned in an optical cavity. The optical cavity confines light in the gain medium, thereby feeding amplified light back through the amplification medium allowing it to be amplified again. Input light resonates between the mirrors while being re-amplified by the gain medium until the lasing threshold is surpassed and laser light is produced. This results in a positive feedback cycle tending to increase the gain G of the optical amplifier.

In a laser, one of the mirrors of the optical cavity is generally known as the high reflector while the other is the output coupler. Typically, the output coupler is partially transparent and emits the output laser beam. In certain embodiments, the invention provides a wavelength dependent reflector as a reflective surface with laser, such as one of the mirrors (e.g., the output coupler) or one of the facets of the gain medium.

A laser can be provided, for example, as a COTS component in a 14-pin butterfly package with either SMF or PMF pigtails. One such exemplary laser is the 980 nm pump laser module with Bragg grating sold under the mark POW-ERPURE 1998 PLM, available from Avanex Corporation (Fremont, Calif.).

In certain embodiments, a gain component such as an specific manner. A gain component includes a gain medium having a gain coefficient g (gain per unit length) that is a function of the optical frequency of the incident signal w. The gain coefficient at a given frequency $g(\omega)$ is given by

$$g(\omega)=g_0/(1+(\omega-\omega_0)^2T^2+P/Ps)$$

where g_0 is the peak gain of the medium, P is the optical power of the signal being amplified, Ps is the saturation power of the gain medium, ω_0 is an atomic transition frequency of the medium, and T is a dipole relaxation time. Where incident light has a frequency ω , a gain medium has a gain coefficient $g(\omega)$ and gain is given by Equation 4:

$$G(\omega) = \exp[g(\omega)LJ]$$
 (4)

where L is a length of the gain medium.

The power of amplified light at a distance z from the input end of a gain medium is given by Equation 5:

$$P(z) = P_{in} \exp(gz) \tag{5}$$

Gain coefficient g has an inverse square relationship to $(\omega - \omega_0)$ (see Equation 3) and power P(z) is exponentially related to gain coefficient g. Thus, the gain of a gain medium is higher for optical frequencies ω closer to ω_0 . FIG. 8 shows gain as a function of wavelength for a typical gain medium. As shown by the peak of the gain curve, the gain medium has a "peak gain".

If light of various wavelengths is amplified by the medium (at powers well below the saturation power Ps of the gain medium), light having a wavelength at or near the peak gain will be amplified to greater powers than light having a wavelength not at or near the peak gain.

For any wavelength of light, if the gain is greater than the loss, lasing can result in which the light is emitted as a laser beam. The conditions at which gain equals loss is the lasing threshold for a frequency of light. The lasing threshold is lowest at the peak gain and light having a wavelength at the peak gain is more readily and more robustly amplified than other wavelengths. Consequently, the gain medium most readily lases light at the peak gain.

Where this lasing is unintended, it is known as parasitic lasing. If light transmitted through the medium has sufficient 15 power, wavelengths near the peak gain will cross the lasing threshold, causing lasing. This parasitic lasing leaches power from the system, reduces coherence length of signal light, and introduces noise into the signal. Due to the shape of the gain curve in a typical gain medium, parasitic lasing 20 is problematic near the peak gain.

Devices and methods of the invention suppress parasitic lasing. In one embodiment, systems and methods of the invention suppress parasitic lasing by wavelength-dependent inhibition of reflection of light transmitted through a 25 gain medium. By providing a system including a gain component and a wavelength dependent reflector, systems of the invention can provide amplified light of a selected wavelength without parasitic lasing at a peak gain.

Materials for use with systems and methods of the invention can be employed to selectively inhibit reflection at the peak gain and not inhibit reflection not at the peak gain. In certain embodiments inhibiting reflection is not at wavelengths both above and below the peak gain. Exemplary materials for use with systems and methods of the invention include surface coatings that inhibit reflection in a wavelength-dependent matter, for example, inhibiting substantially all reflection at a peak gain.

In general, a substrate with a reflective surface in which the surface is coated presents two reflective interfaces. The 40 coated substrate provides an air/coating interface and a coating/substrate interface. A coating can be described in terms of physical thickness t and refractive index n, which together give an optical thickness nt of the coating.

If the reflections from each interface are out of phase by 45 180 degrees (π radians) then those reflections will interfere destructively, cancelling each other out (i.e., no light is reflected and all of the light will be transmitted through the material). To eliminate reflections at a specific wavelength λ , the optical thickness nt of the coating must be an odd 50 number of quarter wavelengths λ of light as shown in Equation 6.

$$nt=N \lambda 4$$
, (6)

where $N=\{1, 2, 3, \dots\}$. Generally, the refractive index n of 55 the coating should be the square root of the refractive index of the substrate, as shown in Equation 7.

$$n_{coating} = \sqrt{n_{substrate}}$$
 (7)

That is, where the substrate is glass, the coating should 60 have a refractive index n of about 1.2 or so. Where multiple reflective coatings are used, cancellation is a product of the relative phase and intensity of the interfering beams. This cancellation can be controlled by controlling the relative optical thicknesses of the layers. For a given combination of 65 coatings, there are typically two combinations of thicknesses that give zero reflectance at a given wavelength. Further-

8

more, two-layer antireflective coatings exhibit a curve of reflectance as a function of wavelength, generally having a V or U shape. This is shown in FIG. 9.

Any material suitable for any antireflective coating may be used. Exemplary materials include metals such as aluminum, silver, or gold or compounds such as magnesium fluoride (MgF₂) in suitable thickness (e.g., single-layer quarter-wavelength coatings or multi-layered). Coated materials are sold under the trademark HEBBAR by CVI Melles Griot (Albuquerque, N. Mex.).

Coatings of the desired thickness can be fabricated by any method known in the art including, for example, vacuum deposition, electron bombardment vaporization, plasma ion-assisted deposition (PIAD), carbon vapor deposition, plasma vapor deposition, and related techniques. In vacuum deposition, a substrate is put in a vacuum chamber along with a metal crucible holding the coating substance. A high current (e.g., 100 A) is passed through the coating material, vaporizing it. Due to the vacuum, the vaporized material disperses to the material to be coated.

Materials for use with systems and methods of the invention can be used to coat a facet of a gain medium or a surface in an optical path such as a mirror. A coated mirror can be any mirror within the optical path of a light source, such as one of the mirrors in a tunable etalon or a reflector in a laser. In certain embodiments an output coupler of a semiconductor optical amplifier is coated with a wavelength dependent reflective material.

Where a mirror is coated with the wavelength dependent material, light at wavelengths not at the peak gain is reflected. In certain embodiments, the invention provides a substrate with a coated reflective surface (e.g., a coated mirror) that reflects light at wavelengths both above and below a peak gain. Inhibiting reflection in a wavelength dependent manner can be used to inhibit reflection at a peak gain of a gain medium of gain component thereby suppressing parasitic lasing. Thus, a light source according to the invention may be operated to produce amplified coherent light at wavelengths other than a peak gain of the gain medium without parasitic lasing near the peak gain.

Where an optical system requires a particular wavelength of amplified light, the light source may include an optical filter module such as a tunable optical filter in optical communication with a gain component. FIG. 10 is a diagram of a light path within an optical filter comprising a Fabry-Perot etalon. Etalons are discussed in Laufer, G., Introduction to Optics and Lasers in Engineering 1996, 476 pages, Cambridge University Press, Cambridge, UK, the contents of which are incorporated by reference herein in their entirety (see, e.g., §6.5 The Fabry-Perot Etalon, pp. 156-162). Optical filters are discussed in U.S. Pat. No. 7,035,484; U.S. Pat. No. 6,822,798; U.S. Pat. No. 6,459,844; U.S. Pub. 2004/0028333; and U.S. Pub. 2003/0194165, the contents of each of which are incorporated by reference herein in their entirety.

An optical filter typically has a peak reflectivity and a background reflectivity. The peak reflectivity indicates an amount of light output (reflected) at the specified wavelength, wherein a desired wavelength can be set (in a tunable filter) by placing mirrors in an etalon an appropriate distance apart. The background reflectivity indicates an amount of light output at wavelengths other than the desired wavelength.

Typical filters might have, for example, a 20% peak reflectivity and an 0.02% background reflectivity. The ratio of these number (10³) defines the filter contrast ratio, expressed in decibels (dB) (here, 30 dB). Thus, if light of a

certain wavelength, say 1200 nm, is intended, the filter will transmit light at 1200 nm as well as a broad spectrum of light at lower power in a ratio of 30 dB.

In some embodiments, systems of the invention include an optical filter that can be tuned to a desired wavelength, 5 i.e., a tunable optical filter. Amplified light of a selected wavelength is obtained by tuning the filter to that wavelength and sending the light into the gain medium with sufficient input power to achieve a desired output power. An optical gain component (e.g., SOA, BOA, or laser) with a 10 wavelength dependent material located in the light path suppress low-level background light across a broad spectrum of wavelengths. When the input power is high enough to successfully amplify a selected frequency not at peak gain, the input power of background light at the peak gain 15 is suppressed, preventing parasitic lasing.

This allows the optical amplifier to amplify light across a broad range of wavelengths without parasitic lasing, thereby increasing the useable range of the tunable optical filter. In this manner, light at wavelengths not at a peak gain can be 20 used effectively, and the gain medium of the optical amplifier does not limit use of a system to a narrow range of wavelengths associated with a peak gain of the gain medium. In this fashion, the tunable range of the tunable optical filter is increased.

In general, the invention provides systems for producing coherent light that include a gain component such as an optical amplifier with a reflector in optical communication with the optical amplifier, in which the reflector inhibits reflection of light at the peak gain and reflects light at 30 wavelengths not at the peak gain, thereby suppressing parasitic lasing. FIG. 11 is a diagram of an optical system according to certain embodiments of the invention. Light 821 is transmitted through filter 825 and along light path 817. Gain component 813 produces amplified coherent light 35 805 with a wavelength dependent material 801 in the light path. Amplified light 805 is sent to downstream component 809 as needed (e.g., an interferometer). The gain component produces coherent near infrared light from incident light delivered by a filter module in optical connection to the gain 40 component. Preferably, the reflector is an output coupler and the gain component is a semiconductor optical amplifier. Systems of the invention further include any other compatible component known in the art. Exemplary components include interferometers, couplers/splitters, controllers, and 45 any other device known in the art. Systems of the invention may include input and output mechanisms, such as an output mechanism configured to be coupled to a fiber optic interferometer or other imaging device. An optical system may include a controller component. For example, systems can 50 include the LDC1300B butterfly LD/TEC controller from Thorlabs (Newton, N.J.). The LD/TEC controller and mount allows a system to be controlled by a computer. In certain embodiments, optical systems are integrated into an optical networking platform such as the Cisco ONS 15500 Dense 55 Wave Division Multiplexer.

In certain embodiments, the system includes an interferometer such as a fiber optic interferometer. An interferometer, generally, is an instrument used to interfere waves and measure the interference. Interferometry includes extracting 60 information from superimposed, interfering waves. Any interferometer known in the art can be used. In certain embodiments, an interferometer is included in a Mach-Zehnder layout, for example, using single mode optical fibers. A Mach-Zehnder interferometer is used to determine 65 the relative phase shift between two collimated beams from a coherent light source and can be used to measure small

10

phase shifts in one of the two beams caused by a small sample or the change in length of one of the paths.

Measuring a phase change in one of two beams from a coherent light is employed in optical coherence tomography (OCT). Commercially available optical coherence tomography systems are employed in diverse applications, including art conservation and diagnostic medicine, e.g., ophthalmology. Recently it has also begun to be used in interventional cardiology to help diagnose coronary artery disease. OCT systems and methods are described in U.S. Pub. 2011/0152771; U.S. Pub. 2010/0220334; U.S. Pub. 2009/0043191; U.S. Pub. 2008/0291463; and U.S. Pub. 2008/0180683, the contents of each of which are hereby incorporated by reference in their entirety.

Various lumen of biological structures may be imaged with aforementioned imaging technologies in addition to blood vessels, including, but not limited, to vasculature of the lymphatic and nervous systems, various structures of the gastrointestinal tract including lumen of the small intestine, large intestine, stomach, esophagus, colon, pancreatic duct, bile duct, hepatic duct, lumen of the reproductive tract including the vas deferens, vagina, uterus and fallopian tubes, structures of the urinary tract including urinary collecting ducts, renal tubules, ureter, and bladder, and structures of the head and neck and pulmonary system including sinuses, parotid, trachea, bronchi, and lungs.

In OCT, a light source delivers a beam of light to an imaging device to image target tissue. Within the light source is an optical amplifier and a tunable filter that allows a user to select a wavelength of light to be amplified. Wavelengths commonly used in medical applications include near-infrared light, for example, 800 nm for shallow, high-resolution scans or 1700 nm for deep scans.

Generally, there are two types of OCT systems, common beam path systems and differential beam path systems, that differ from each other based upon the optical layout of the systems. A common beam path system sends all produced light through a single optical fiber to generate a reference signal and a sample signal whereas a differential beam path system splits the produced light such that a portion of the light is directed to the sample and the other portion is directed to a reference surface. The reflected light from the sample is recombined with the signal from the reference surface for detection. Common beam path interferometers are further described for example in U.S. Pat. No. 7,999,938; U.S. Pat. No. 7,995,210; and U.S. Pat. No. 7,787,127, the contents of each of which are incorporated by reference herein in its entirety.

In a differential beam path system, amplified light from a light source is input into an interferometer with a portion of light directed to a sample and the other portion directed to a reference surface. A distal end of an optical fiber is interfaced with a catheter for interrogation of the target tissue during a catheterization procedure. The reflected light from the tissue is recombined with the signal from the reference surface forming interference fringes (measured by a photovoltaic detector) allowing precise depth-resolved imaging of the target tissue on a micron scale. Exemplary differential beam path interferometers are Mach-Zehnder interferometers and Michelson interferometers. Differential beam path interferometers are further described for example in U.S. Pat. No. 7,783,337; U.S. Pat. No. 6,134,003; and U.S. Pat. No. 6,421,164, the contents of each of which are incorporated by reference herein in its entirety.

In certain embodiments, the invention provides a differential beam path OCT system with intravascular imaging capability as illustrated in FIG. 12. For intravascular imag-

ing, a light beam is delivered to the vessel lumen via a fiber-optic based imaging catheter 826. The imaging catheter is connected through hardware to software on a host workstation. The hardware includes an imagining engine 859 and a handheld patient interface module (PIM) 839 that includes 5 user controls. The proximal end of the imaging catheter is connected to PIM 839, which is connected to an imaging engine as shown in FIG. 12.

As shown in FIG. 13, the imaging engine 859 (e.g., a bedside unit) houses a power supply 849, light source 827, 10 interferometer 931, and variable delay line 835 as well as a data acquisition (DAQ) board 855 and optical controller board (OCB) 854. A PIM cable 841 connects the imagine engine 859 to the PIM 839 and an engine cable 845 connects the imaging engine 859 to the host workstation.

FIG. 14 shows light path in an exemplary embodiment of the invention. Light for image capture originates within the light source 827. This light is split between an OCT interferometer 905 and an auxiliary interferometer 911. The OCT interferometer generates the OCT image signal and the 20 auxiliary, or "clock", interferometer characterizes the wavelength tuning nonlinearity in the light source and generates a digitizer sample clock.

In certain embodiments, each interferometer is configured in a Mach-Zehnder layout and uses single mode optical 25 fibers to guide the light. Fibers are connected via either LC/APC connectors or protected fusion splices. By controlling the split ratio between the OCT and auxiliary interferometers with splitter 901, the optical power in the auxiliary interferometer is controlled to optimize the signal in the 30 auxiliary interferometer. Within the auxiliary interferometer, light is split and recombined by a pair of 50/50 coupler/ splitters.

Light directed to the main OCT interferometer is also split by splitter 917 and recombined by splitter 919 with an 35 asymmetric split ratio. The majority of the light is guided into the sample path 913 and the remainder into a reference path 915. The sample path includes optical fibers running through the PIM 839 and the imaging catheter 826 and terminating at the distal end of the imaging catheter where 40 the image is captured.

Typical intravascular OCT involves introducing the imaging catheter into a patient's target vessel using standard interventional techniques and tools such as a guidewire, guide catheter, and angiography system. When operation is 45 triggered from the PIM or control console, the imaging core of the catheter rotates while collecting image data that it delivers to the console screen. Rotation is driven by spin motor 861 while translation is driven by pullback motor 865, shown in FIG. 15 Blood in the vessel is temporarily flushed 50 with a clear solution while a motor translates the catheter longitudinally through the vessel.

In certain embodiments, the imaging catheter has a crossing profile of 2.4 F (0.8 mm) and transmits focused OCT microprocessors running firmware in both the PIM and imaging engine control the system. The imaging catheter includes a rotating and longitudinally-translating inner core contained within an outer sheath. Using light provided by the imaging engine, the inner core detects reflected light. 60 The reflected, detected light is transmitted along the sample path to be recombined with the light from the reference path.

A variable delay line (VDL) 925 on the reference path uses an adjustable fiber coil to match the length of the reference path 915 to the length of the sample path 913. The 65 reference path length is adjusted by translating a mirror on a lead-screw-based translation stage that is actuated electro-

mechanically by a small stepper motor. The free-space optical beam on the inside of the VDL 925 experiences more delay as the mirror moves away from the fixed input/output fiber. Stepper movement is under firmware/software control.

Light from the reference path is combined with light from the sample path. This light is split into orthogonal polarization states, resulting in RF-band polarization-diverse temporal interference fringe signals. The interference fringe signals are converted to photocurrents using PIN photodiodes 929a, 929b, . . . on the OCB 851 as shown in FIG. 14. The interfering, polarization splitting, and detection steps are done by a polarization diversity module (PDM) on the OCB. Signal from the OCB is sent to the DAQ 855, shown in FIG. 13. The DAQ includes a digital signal processing (DSP) microprocessor and a field programmable gate array (FPGA) to digitize signals and communicate with the host workstation and the PIM. The FPGA converts raw optical interference signals into meaningful OCT images. The DAQ also compresses data as necessary to reduce image transfer bandwidth to 1 Gbps (e.g., lossily compressing frames using a JPEG encoder).

In certain embodiments, the invention provides a light source for OCT including an optical filter, a gain component, and a wavelength dependent material to selectively inhibit reflection at a peak gain of a gain medium of the optical amplifier.

Any filter known in the art compatible with the invention may be used including, for example, a tunable optical filter. The filter is included to deliver light of a specified wavelength into the optical amplifier. The filter typically has a peak reflectivity and a background reflectivity. In some embodiments, a system includes a commercial, off-the-shelf (COTS) filter. One exemplary filter for use with the invention is filter module TFM-687 by Axsun Technologies, Inc. (Billerica, Mass.). An exemplary tunable optical filter exhibits 20% reflectivity and a 29 dB contrast ratio. Although a tunable optical filter from Asxun Technologies has been described as a possible tunable optical filter to be used with the invention, any tunable optical filter, such as is well understood in the art, may be used in the present invention.

Any optical amplifier or laser known in the art and compatible with the invention may be used as the gain component including, for example, a semiconductor optical amplifier. The amplifier amplifies the light to a sufficient output power for imagining by OCT. The amplifier typically has a semiconductor gain medium and an optical cavity. In some embodiments, a system includes a COTS amplifier. One exemplary optical amplifier for use with the invention is booster optical amplifier serial number BOA1130S, BOA1130P, or BOA-8702-11820.4.B01 from Thorlabs (Newton, N.J.). An exemplary optical amplifier has a center wavelength of 1285 nm and a small signal gain of 30 dB with a chip length of 1.5 mm (See specifications in FIG. 4)

A mirror can be coated with wavelength dependent mateimaging light to and from the vessel of interest. Embedded 55 rial, for example and as well known in the art, as shown in FIG. 9. Material coatings are available from Unioriental Optics Co., Ltd. (Zhong Guan Cun Science Park, Beijing, China).

> In certain embodiments, the invention provides systems and methods for amplifying light for OCT such as diagrammed in FIG. 13. Exemplary components of light source 827 are illustrated in FIG. 11. Tunable optical filter 825 provides light to gain component 813 and the system further includes wavelength dependent mirror 801. Gain component 813 including a gain medium is provided by a BOA having specification as shown in FIGS. 4-5 (e.g., generally having a form factor as illustrated in FIG. 6). Filter 825 set at near

infrared wavelengths produces light having wavelengths at a peak gain of the gain medium (e.g., about 1300 nm) and wavelengths not at a peak gain (e.g., about 1200 nm). This light is transmitted through the gain medium. Wavelength dependent mirror 801 exhibits reflectivity in a wavelength 5 dependent manner as shown by the curve in FIG. 9 and thus inhibits substantially all reflection at wavelengths at the peak gain, thereby allowing amplification of light at wavelengths not at the peak gain. Light source 827 thus provides light at wavelengths below the peak gain (e.g., at about 1200 nm) to 10 interferometer 831 without parasitic lasing and can similarly provide light at wavelengths above the peak gain. Tunable optical filter 825 in light source 827 included within imaging engine 927 (FIG. 13) can be tuned to wavelengths below and above the peak gain to a greater degree than without 15 wavelength dependent reflector 801, and the system operates without parasitic lasing to produce coherent near infrared light.

INCORPORATION BY REFERENCE

References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated 25 herein by reference in their entirety for all purposes.

EQUIVALENTS

Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, 35 exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.

What is claimed is:

- 1. An optical coherence tomography (OCT) system with $_{40}$ intravascular imaging capability, said OCT system comprising:
 - a fiber-optic based imaging catheter; and
 - an imaging engine connected to the fiber-optic based imaging catheter, said imaging engine comprising a 45 light source and said light source comprising:
 - a gain medium having a peak gain at a near infrared wavelength; and
 - a mirror comprising a wavelength dependent material having a minimum reflectivity at the near infrared wavelength, thereby allowing the gain medium to amplify light at wavelengths not at the peak gain.
- 2. The OCT system of claim 1, wherein the mirror reflects light at a desired wavelength.
- 3. The OCT system of claim 1, wherein the wavelength 55 dependent material does not inhibit reflection at wavelengths above and below the peak gain.
- **4**. The OCT system of claim **1**, wherein the wavelength dependent material constitutes an output coupler.
- 5. The OCT system of claim 1, further comprising an output coupler.

14

- **6**. An optical coherence tomography (OCT) system with intravascular imaging capability, said OCT system comprising:
 - a fiber-optic based imaging catheter; and
 - an imaging engine connected to the fiber-optic based imaging catheter, said imaging engine comprising a light source and said light source comprising:
 - an optical amplifier comprising a gain medium having a peak gain at a near infrared wavelength; and
 - a reflector in optical communication with the optical amplifier and comprising a wavelength dependent material having a minimum reflectivity at the near infrared wavelength, wherein the reflector inhibits reflection of light at wavelengths at the peak gain and reflects light at wavelengths not at the peak gain, thereby suppressing parasitic lasing.
- 7. The OCT system of claim 6, wherein the optical amplifier produces coherent near-infrared light.
- **8**. The OCT system of claim **6**, further comprising a filter module in optical connection to the optical amplifier.
- 9. The OCT system of claim 6, wherein the reflector is an output coupler.
- 10. The OCT system of claim 6, wherein the optical amplifier is a semiconductor optical amplifier.
- 11. The OCT system of claim 6 further comprising an output mechanism configured to be coupled to a fiber optic interferometer.
- 12. A method for intravascular imaging, comprising the steps of:
 - transmitting light comprising peak gain and non-peak gain wavelengths through a gain medium, wherein the peak gain is at a near infrared wavelength;
- inhibiting substantially all reflection at peak gain wavelengths, thereby allowing amplification of light at nonpeak gain wavelengths directing the amplified light to an optical coherence tomography (OCT) system with intravascular imaging capability, said OCT system comprising:
 - a fiber-optic based imaging catheter;
 - a patient interface module (PIM); and
 - an imaging engine;
 - wherein the fiber-optic based imaging catheter is optically coupled to the PIM and the PIM is optically coupled to the imaging engine.
- 13. The method of claim 12, wherein reflection is not inhibited at wavelengths both above and below the wavelengths at the peak gain.
- 14. The method of claim 12, wherein the gain medium comprises a semiconductor.
- 15. The method of claim 14, further comprising lasing the light at one of the non-peak gain wavelengths.
- 16. The method of claim 14 wherein the amplified light is coherent near-infrared light.
- 17. The method of claim 12, wherein the inhibiting step comprises providing a mirror to reflect the light at non-peak gain wavelengths and inhibit reflection of light at the wavelengths at the peak gain.
- 18. The method of claim 17, wherein the mirror is an output coupler.

* * * * *